

Cortical Mechanisms of Visual Hypersensitivity in Women At Risk for Chronic Pelvic Pain

Matthew J. Kmiecik<sup>1,2</sup>, Frank F. Tu<sup>1,2</sup>, Rebecca L. Silton<sup>3</sup>, Katlyn E. Dillane<sup>1</sup>, Genevieve E.

Roth<sup>1</sup>, Steven E. Harte<sup>4</sup>, & Kevin M. Hellman<sup>1,2</sup>

<sup>1</sup> Department of Ob/Gyn, NorthShore University HealthSystem, Evanston, IL, United States

<sup>2</sup> Department of Ob/Gyn, Pritzker School of Medicine, University of Chicago, Chicago, IL,  
United States

<sup>3</sup> Department of Psychology, Loyola University Chicago, Chicago, IL, United States

<sup>4</sup> Chronic Pain and Fatigue Research Center, Department of Anesthesiology, University of  
Michigan, Ann Arbor, MI

**Abstract**

Multisensory hypersensitivity (MSH), which refers to persistent discomfort across sensory modalities, is a risk factor for chronic pain. Developing a better understanding of the neural contributions of disparate sensory systems to MSH may clarify its role in the development of chronic pain. We recruited a cohort of women ( $n=147$ ) enriched with participants with menstrual pain at risk for developing chronic pain. Visual sensitivity was measured using a periodic pattern-reversal stimulus during EEG. Self-reported visual unpleasantness ratings were also recorded. Bladder pain sensitivity was evaluated with an experimental bladder-filling task associated with early clinical symptoms of chronic pelvic pain. Visual stimulation induced unpleasantness was associated with bladder pain and evoked primary visual cortex excitability; however, the relationship between unpleasantness and cortical excitability was moderated by bladder pain. Thus, future studies aimed at reversing the progression of MSH into chronic pain should prioritize targeting of cortical mechanisms responsible for maladaptive sensory input integration.

*Keywords:* chronic pain; visceral sensitivity; multisensory hypersensitivity; steady-state visual evoked potential (SSVEP); dysmenorrhea

### Cortical Mechanisms of Visual and Visceral Hypersensitivity

Multisensory hypersensitivity (MSH), which refers to persistent discomfort from multiple sensory pathways, is a common symptom of sensory processing disorders and chronic pain (Bar-Shalita et al., 2019; Bennett, 1999; Ben-Sasson et al., 2009; Molholm et al., 2020). Conceptually, MSH is related to the increased tendency to report somatic symptoms (previously also known as somatization), and is among the foremost risk factors for chronic pain (McBeth et al., 2001). Increased sensitivity to tactile pressure, light, sound, and odors exemplify MSH and are a common phenotype associated with chronic overlapping pain conditions (Geisser et al., 2008; Harte et al., 2016; Hollins et al., 2009; Martenson et al., 2016; Montoya et al., 2006; Schrepf et al., 2018). Furthermore, individuals with chronic pelvic pain conditions experience increased sensitivity to visceral input (e.g., uterus, bladder, bowel) with concomitant mechanical and thermal hypersensitivity in the periphery (Hellman et al., 2020; Larsson et al., 2012; Payne et al., 2017). Many have proposed that the “centralized” mechanism of pain sensitization is responsible for MSH (Arendt-Nielsen et al., 2017; Curatolo et al., 2006; Phillips & Clauw, 2011); however, it remains unclear whether increased sensitivity is due to sensory pathway hyperexcitability (i.e., efferent/bottom-up) or mechanisms involving higher cortical modulation and integration (i.e., afferent/top-down). Additionally, the extent to which visceral pain is an element of MSH and associated with hypersensitivity in other modalities, such as vision, is unknown. Our understanding of MSH is limited because ideal at-risk cohorts that include evoked responses are rarely studied with sufficient statistical power (i.e., sample size) or temporal precision. A better understanding of the interaction between sensory and integrative processing may inform therapies addressing psychological factors involved in chronic pain conditions, including somatic symptoms (Fishbain et al., 2009) and pain catastrophization (Galambos et al., 2019; Quartana et

al., 2009). For instance, understanding how early-to-late cortical mechanisms, as well as visceral pain, correspond to sensory unpleasantness would suggest brain regions for targeted interventions.

To investigate clinically relevant mechanisms responsible for MSH, we have identified a cohort of women with symptoms of MSH and at-risk for chronic pelvic pain. This cohort of women with dysmenorrhea (episodic menstrual pain) also have increased bladder pain (Hellman et al., 2020) that correlates with clinical symptoms of chronic pelvic pain (Hellman et al., 2018; Tu et al., 2013, 2017). Quantitative sensory testing in this cohort demonstrated widespread reduced pain thresholds and impaired endogenous pain modulation, further indicating increased risk for developing chronic pain (Hellman et al., 2020; Yarnitsky, 2010). To evaluate the visceral contributions to MSH in the present study, we used our validated noninvasive bladder filling task (Tu et al., 2013) and self-reported menstrual pain. We evaluated the visual contributions to MSH by presenting this cohort with an aversive but non-painful passive visual stimulus while recording scalp electroencephalography (EEG). Participants viewed a rapidly reversing checkerboard pattern presented across increasing intensities of brightness and rated their perceived unpleasantness. Pattern-reversal visual stimuli are known to elicit a steady-state visual evoked potential (SSVEP) evident in the broadband EEG spectra at the presentation frequency (Norcia et al., 2015; Vialatte et al., 2010). SSVEPs are robust measures of cortical excitability to a visual stimulus with sources primarily located in primary visual cortex (V1) and secondary visual cortex sensitive to motion (V5/MT; Di Russo et al., 2007).

Given previous literature linking visual discomfort and cortical measures across various visual stimulus parameters (Haigh et al., 2013; O'Hare, 2016; Patterson Gentile & Aguirre, 2020), we hypothesized that brightness intensity would modulate SSVEP amplitudes,

particularly in V1 (electrode Oz) . Given the comorbidity of MSH in chronic visceral pain, we hypothesized that the relationship between visual unpleasantness and cortical excitability would be similarly affected by bladder pain. Notably, in other research that did not evaluate bladder pain, menstrual pain and somatic symptoms were among the factors most strongly associated with chronic pelvic pain (Westling et al., 2013). In the present study, we accounted for somatic symptoms and menstrual pain to differentiate the contributions of these common comorbid symptoms to behavioral and neural measures of MSH. Analysis of the relationship of self-reported responses to visceral and visual provocation with cortical recordings allows us to address the following questions: 1) Do women who exhibit visceral pain sensitivity (either menstrual or bladder) report heightened visual evoked unpleasantness? 2) Is visual discomfort associated with increased cortical excitability? If so, is this relationship moderated by visceral sensitivity?

## **Method**

### **Participants**

The present investigation was part of a larger clinical trial “Deciphering the Hormonal and Nociceptive Mechanisms Underlying Bladder Pain” (NCT02214550) that enrolled 378 reproductive-age (18-45) women between 2014-2020. Participants were recruited by flyers posted on local college campuses, advertisements on public transportation, and by referral from nearby gynecology clinics. Potential participants that passed an eligibility screening over the phone were scheduled for an initial screening visit. Original inclusion criteria as part of a larger longitudinal trial included controls, dysmenorrhea participants, and chronic pain participants. Control participants had pain  $\leq 3/10$  with menses on a 0-10 numerical rating scale (NRS, 0 – no pain, 10 – worst pain imaginable) and no concurrent chronic pain diagnoses. Dysmenorrhea

participants had self-reported pain  $> 4/10$  with menses on average,  $\geq 4$  as demonstrated by diary data. Participants with chronic pain conditions other than dysmenorrhea were excluded from these analyses to avoid potential confounding of the many factors (e.g., anxiety, depression, catastrophizing) that are awry in chronic pain (Geisser et al., 1994).

Controls and dysmenorrhea participants were pooled for dimensional analyses following our observation that women with dysmenorrhea often have heightened bladder pain ratings compared to control participants (Tu et al., 2013). This dimensional strategy is recommended to avoid artificial boundaries and artifacts associated with historical diagnostic criteria, increase relevance to preclinical forms of disease, and improve statistical power (Cohen, 1983; Royston et al., 2006; Yee et al., 2015). Exclusion criteria for the present study included: a) presence of active pelvic or abdominal malignancies, b) absence of regular menses, c) active genitourinary infection in the last four weeks, d) unable to read or comprehend the informed consent in English, e) unwilling to undergo pelvic examination/testing, f) presence of hypertension or risk for developing hypertension, g) unwilling to withdraw from oral contraceptives for two months before the study visit, h) inadequate visual acuity to identify 3mm letters on a monitor 1 m away, or i) hairstyles that precluded EEG cap placements.

From the 378 enrolled participants, 93 were classified into groups (e.g., painful bladder syndrome, chronic pain) that are out of scope for the present investigation, 95 did not complete the assessment visit, 40 were excluded due to technical difficulties (e.g., poor EEG quality resulting from equipment malfunction, capping difficulties due to hairstyle, etc.), two declined to participate in the EEG portion due to migraine sensitivity, and one was excluded due to recreational/illicit substance during the testing appointment; therefore, data from a total of 147 women were included in the present investigation. All participants provided written consent and

were compensated monetarily for their time. All procedures followed the principles and guidelines stated in the Declaration of Helsinki and were approved by the NorthShore University HealthSystem's Institutional Review Board.

### **Procedure**

At an initial screening session, participants completed questionnaire measures encompassing medical, surgical, psychological, and gynecological history. A full list of all questionnaires administered in the larger clinical trial are reported elsewhere (Tu et al., 2020); however, those pertinent in the present investigation are described here and reported in Table 1. In particular, a subset of questions from the Brief Symptom Inventory (BSI; Derogatis & Melisaratos, 1983) representing the somatic symptom subscale evaluated the psychological distress related to the perception of bodily discomfort. Participants rated on a 5-point scale of distress a series of questions that assessed perceptions of bodily pain, such as “Faintness or dizziness”, “Pains in heart or chest”, “Numbness or tingling in parts of your body”, etc. Scores were summed across these questions for each participant and provided a total BSI score, hereafter referred to as “somatic symptoms.”

A standardized pelvic exam was performed by a gynecologist (FFT) to identify potential causes of menstrual pain on the first 98 participants (Hellman et al., 2018). Potential clinical exam findings were only observed in eight participants and followed up with ultrasonography. Among these eight participants, three participants had small pelvic cysts (<2.5 x 3.0 cm), and one had subserosal and intramural leiomyomata (<2.5 x 2.5 cm). We discontinued performing pelvic exams to limit potential discomfort and inconvenience, given that most recruited participants had exam profiles consistent with primary dysmenorrhea.

Eligible participants with dysmenorrhea were subsequently scheduled for a mid-luteal

phase assessment visit (approximately 17-25 days post-onset of menses). The menstrual cycle state was confirmed with urinary tests for luteinizing hormone surges on days 10-17 (Greenspan et al., 2007). Participants were asked to rate the “average amount of cramping or pain you have experienced during your menstrual period over the past 3 months when not taking any painkillers and on the worst day of your period” using a 0-100 Visual Analog Scale (VAS; 0 – no pain, 100 – worst pain imaginable) (Hjermstad et al., 2011). This question was asked during the luteal phase and thus avoided complications due to variable painkiller use. The average intensity of menstrual pain was confirmed using electronic daily diaries over a full menstrual cycle before the assessment visit (Hellman et al., 2018).

During their mid-luteal phase assessment visit, participants were asked to avoid taking short-acting, over-the-counter analgesics (e.g., ibuprofen, acetaminophen), short-acting opioids (e.g., hydrocodone or oxycodone), and caffeine for at least six hours before arrival. Participants were instructed to also avoid longer-acting over-the-counter analgesics (e.g., naproxen) for at least twelve hours before arrival. We performed comprehensive quantitative sensory testing (Hellman et al., 2020) and non-invasive experimental bladder distension on all participants to assess their bladder pain (Hellman et al., 2018; Tu et al., 2013). Our bladder test mimics clinical retrograde cystometry, starting with an emptied bladder. After oral ingestion of 20 oz of water, participants were instructed to report when they reached three standard levels of bladder urgency: first sensation, first urge to void, and maximal capacity (Abrams et al., 2002). At baseline and each of these time points, three-dimensional sonographic measurements of the bladder were obtained (GE Voluson 750, Wauwatosa, WI), and participants rated their bladder pain and urgency on a 10 cm VAS using a tablet computer. Experimental bladder pain assessment was capped at two hours, even if participants did not reach maximal capacity.



Previous investigations from our laboratory have demonstrated that bladder pain ratings at first urge to void is a specific sign of additional bladder pain sensitivity that is observed on retrospective surveys and diaries correlated with clinical markers of bladder pain (Hellman et al., 2018, 2020); therefore, the first urge bladder pain ratings from the bladder distension task, referred to hereafter as “bladder pain”, were used as a moderating factor in regression modeling. After completing this task, we confirmed that bladder pain had returned to baseline levels before beginning the EEG task.


### ***EEG Instrumentation***

Participants were then prepared for EEG recording. Simultaneously, the room was darkened to less than 10 lux ambient light to allow the participant to adapt sufficiently for the visual task. Participants were instrumented with 32 Ag/AgCl active electrodes arranged in the International 10-20 montage (Brain Vision ActiCap). EEG was recorded at 500Hz (1 Hz high-pass and 250 Hz low-pass 20 dB/decade Butterworth filter) using a Brain Vision actiChamp 24-bit A/D amplifier with Pycorder software (BrainVision, NC). Facial and eye movements were recorded from electrodes placed above the right eye, below the left eye, and in the middle of the brow. Electrode impedances were kept below manufacturer guidelines for active electrodes (25 k $\Omega$ ). The left mastoid served as the online reference, and FPz served as the ground electrode. Participants were instructed to avoid clenching, blinking, speaking, and any facial muscle activity. Standard technical quality inspections were also performed (e.g., requesting participants to blink and verifying signal changes in real-time) throughout the recording. During instrumentation, EEG data were examined to evaluate whether participants were compliant with instructions.

### ***EEG Experimental Task***

We verified sufficient acuity for the visual stimulation task by asking participants to identify eight lines each containing six letters ranging in size from 5 mm to 2 mm. Participants performed the task seated one meter from a 41x30 cm computer monitor with a 100 Hz refresh rate at 23° viewing angle. The same monitor and distance was used for the visual task described below. Stimulus presentation and onset of physiological data collection were controlled by E-prime 2.0 (Psychology Software Tools, PA).

Five blocks of a blue/yellow checkerboard with contrasts (positive and negative flips) alternating at 25 Hz were presented for 20 seconds each (Harte et al., 2016). This 25Hz stimulus frequency was selected because it aligned with the monitor's refresh rate, produced an irritating flicker, and resided within the frequency range shown to produce robust SSVEPs (Zhu et al., 2010). Each block contained a single maximal brightness intensity (1, 30, 60, 90 or 120 lux) obtained by adjusting the contrast of the image focused on a fixed crosshair centered in the middle of a solid background. Block order was randomized across participants. Participants were instructed to focus on a fixed crosshair centered in the middle of the screen. After each block, participants rated the unpleasantness of the stimuli using the Gracely Box Scale (Gracely & Kwilosz, 1988; Petzke et al., 2005) that lists the numbers 0 to 20 in descending order next to a set of verbal anchors with logarithmically placed validated positions (see Figure 1).



**Figure 1. Visual stimulation task presented during EEG recording and designed to elicit an SSVEP.** a) Participants viewed an alternating blue-yellow checkerboard pattern with positive and negative reversals across five different intensities of brightness modulated with monotonically increasing lux (i.e., brightness intensity). b) Checkerboards alternated at 25Hz and were presented for 20 seconds before an unpleasantness rating for each brightness intensity. Block order was randomized across participants. c) Participants’ unpleasantness ratings were measured using the Gracely Box Scale with textual descriptors.

**EEG Data Reduction**

EEG data were processed in MATLAB using the EEGLAB toolbox (Delorme & Makeig, 2004). EEG data were re-referenced to an average mastoid reference (i.e., the average of the left

and right mastoid channels), down-sampled to 256Hz for increased computational efficiency without loss of frequency-based resolution (i.e., Nyquist frequency), and digitally filtered using a 1Hz Hamming windowed sinc finite impulse response (FIR) high-pass filter (-6 dB half-amplitude cutoff, 2Hz transition bandwidth). Line noise (i.e., 60Hz) was removed using the Cleanline EEGLAB plugin (Mullen, 2012). Preprocessed data were then visually inspected and noisy sections of continuous EEG were removed. Clean segments of continuous EEG were submitted to an infomax independent component analysis (ICA) using the “runica” algorithm in EEGLAB (Makeig et al., 1997). Artifactual components were identified ( $p > .6$ ) and removed automatically by the Multiple Artifact Rejection Algorithm (MARA; Winkler et al., 2011) EEGLAB plugin. Continuous EEG was then reconstructed from the remaining independent components and noisy channels spherically interpolated if they maintained uncharacteristic signals throughout the recording (e.g., disconnected channels). Two-second epochs with one-second overlap were extracted from each of the five 20 second stimulation blocks and subjected to artifact rejection using a  $\pm 100\mu\text{V}$  threshold that excluded only 11 epochs (< 1% of eligible epochs). To reduce the spreading of the signal on the scalp due to volume conduction effects and increase topographical specificity, we applied a surface Laplacian spatial filter using the CSD MATLAB Toolbox (Kayser, 2009; Kayser & Tenke, 2006) on the extracted epochs before spectral power calculations that utilized Fast Fourier Transform with Hamming window taper. Power spectral density (PSD) estimates at 25Hz, which was our experimentally controlled visual stimulation frequency, were averaged across the 2-second epochs within each of the five stimulation brightness intensities for the visual task. Therefore, each participant had five PSD estimates used for regression modeling.

### **Statistical Analyses**

These data were analyzed using multilevel models (MLMs; i.e., linear mixed models) with random-effects intercepts and slopes to model brain-behavior relationships using a model comparison approach (Judd et al., 2017). To verify that the visual stimulation reliably evoked the expected neural activity, first level models estimated cortical PSD at 25Hz as a function of linearly increasing brightness separately for each participant:

$$\widehat{PSD}_{i,j} = b_0 + b_1(\text{brightness}) \text{ (Eq. 1)}$$

Where  $i$  refers to each participant, while  $j$  refers to each electrode. Values for increasing brightness intensities were mean centered: -2, -1, 0, 1, 2. The participants' regression estimates from first level models were used as dependent variables in second level models that estimated variations in intercepts (i.e., PSD at average intensities of stimulation brightness):

$$\hat{b}_{0,j} = \gamma_0 \text{ (Eq. 2)}$$

and slopes (i.e., change in PSD with each intensity of brightness):

$$\hat{b}_{1,j} = \gamma_0 \text{ (Eq. 3)}$$

To evaluate the relationship between task evoked cortical excitability and sensory unpleasantness, first level models estimated participant reports of unpleasantness as a function of increasing stimulation brightness and cortical excitability measured via 25Hz PSD estimates (i.e., SSVEP amplitude):

$$\widehat{Unpleasantness}_{i,j} = b_0 + b_1(\text{brightness}) + b_2(\text{PSD}) \text{ (Eq. 4)}$$

Where  $i$  refers to each participant, while  $j$  refers to each electrode. Both stimulation brightness and PSD were mean centered. The participants' regression estimates from first level models were used as dependent variables in second level models that additionally included the mean centered moderating variables of menstrual pain, bladder pain, and somatic symptoms. These second-level models specifically estimated the contribution of experimentally measured bladder pain—a

visceral form of experimental MSH—while controlling for menstrual pain and non-specific somatic symptoms. Therefore, three second level models were estimated that evaluated these moderating factors on: average participant unpleasantness ratings at average intensities of stimulation brightness and PSD (i.e., intercepts):

$$\hat{b}_{0,j} = \gamma_0 + \gamma_1(\text{menstrual pain}) + \gamma_2(\text{somatic symptoms}) + \gamma_3(\text{bladder pain}) \text{ (Eq. 5)}$$

slope effects of stimulation brightness intensities:

$$\hat{b}_{1,j} = \gamma_0 + \gamma_1(\text{menstrual pain}) + \gamma_2(\text{somatic symptoms}) + \gamma_3(\text{bladder pain}) \text{ (Eq. 6)}$$

and slope effects of PSD:

$$\hat{b}_{2,j} = \gamma_0 + \gamma_1(\text{menstrual pain}) + \gamma_2(\text{somatic symptoms}) + \gamma_3(\text{bladder pain}) \text{ (Eq. 7)}$$


We hypothesized that unpleasantness ratings would be modulated by brightness intensities and cortical excitability. Additionally, we hypothesized that these relationships would be moderated by sensory components of MSH, i.e., bladder pain controlling for menstrual pain and non-specific somatic symptoms. We predicted the primary effect of moderation would occur at Oz, given that the neural generators of pattern reversal SSVEPs are located in primary visual cortex (V1) and areas that are sensitive to motion (V5/MT) (Di Russo et al., 2007; Norcia et al., 2015). To investigate the effects at the remaining 31 electrode sites, MLMs were computed and corrected for multiple comparisons using false discovery rate (FDR; Benjamini & Hochberg, 1995).

Statistical analyses were performed in R (version 3.6.3; R Core Team, 2020) and RStudio (version 1.2.5033) using the *dplyr* (Wickham et al., 2020), *broom* (Robinson & Hayes, 2020), and *lmSupport* (Curtin, 2018) packages, whereas figures were prepared using *ggplot2* (Wickham, 2016), *patchwork* (Pederson, 2019), and *RColorBrewer* (Neuwirth, 2014).

## Results

### Visual stimulation robustly modulated 25Hz SSVEP power spectral density (PSD)

As expected, the visual task effectively elicited a 25Hz SSVEP that increased in PSD with increasing brightness intensities, demonstrating robust stimulation of visual cortex (Figure 2). Specifically, for every increase in brightness intensity we observed an average increase of 2.1 95% CI [1.9, 2.2] dB of 25Hz PSD at Oz ( $p < .001$ ; see Table 2). Put differently, participants' 25Hz PSD increased an average of 10dB across all brightness intensities (1-120 lux). Although this effect was expected and largest at Oz (partial eta-squared [ $\eta_p^2$ ] = .78), we emphasize that significant linear increases in 25Hz PSD occurred at every electrode site across the scalp even when correcting for multiple comparisons (see Supplementary Table 1). Thus, our visual task effectively evoked widespread cortical excitability precisely synchronized to our stimulus frequency in proportion to stimulus brightness intensity.




**Figure 2. The unpleasant checkerboard stimuli presented at 25Hz evoked widespread robust SSVEPs focused at Oz.** *Left.* Broadband PSD averaged across the five presented brightness intensities for all participants shows a clear peak at the 25Hz SSVEP alternating checkerboard frequency. Grey shading denotes 95% confidence interval. *Middle.* Topographically plotted intercepts demonstrated elevated PSD estimates toward occipital electrode sites. *Right.* Topographically plotted regression slopes show scalp-wide positive slopes, especially at occipital sites and Oz, demonstrating an increase in SSVEP PSD estimates with increasing brightness intensities. All topographic sites for intercept and slope effects were significant after correcting for multiple comparisons ( $p_{FDR} < .001$ ).

### Brain-Behavior Relationship Moderated by Menstrual Pain, Somatic Symptoms, and

## Bladder Pain

The MLM regression procedure modeled brain-behavior relationships and how these relationships were moderated by pain and somatic symptoms. Menstrual pain, somatic symptoms, and bladder pain were positively correlated with each other (see Table 3 for descriptive statistics) and demonstrated variability across their respective ranges (see Figure 3).




**Figure 3. Density plots of moderating pain and somatic symptom variables in second level regression models.** The participants had a wide range of menstrual pain, bladder pain, and somatic symptom scores amenable for regression modeling. Y-axis (density) represents the concentration of points about a continuous x-axis measure. VAS = visual analog scale (0 – no pain, 100 – worst pain imaginable).

### *Intercept Model*

The intercept model estimated how the participants' unpleasantness ratings following visual stimulation were moderated by self-reported menstrual pain, somatic symptoms, and bladder pain (Table 4). Collapsing across all brightness intensities, participants rated the unpleasantness associated with visual stimulation as a Gracely Box Scale (GBS) rating of 8.0 [7.4, 8.6] corresponding with the descriptors “annoying” and “unpleasant” (see Table 4). Menstrual pain and somatic symptoms did not moderate mean unpleasantness ratings. However, we observed a



positive linear association between bladder pain and mean unpleasantness ratings, suggesting that participants with increased bladder pain rated the visual stimulation as more unpleasant (see Figure 4a). On average, participants' unpleasantness ratings increased by 1.0 GBS point per 15-point increase in bladder pain ( $\eta_p^2 = .06$ ,  $p = .003$ ).



**Figure 4. Bladder pain and cortical activity were independently associated with increased unpleasantness during the visual task.** a) Partial regression scatter plots depict the positive relationship between bladder pain and participants' mean unpleasantness ratings averaged across brightness intensities accounting for menstrual pain and somatic symptoms. b) Topographic plots of regression slopes testing the intercepts from the brightness and PSD models. Oz was our *a priori* electrode of interest. Raw (grey) and averaged (red) slopes across all participants are plotted below to demonstrate that increases in brightness intensity and 25Hz PSD resulted in concomitant increases in participant unpleasantness ratings when accounting for one another. PSD = power spectral density.

### **Brightness Model**

The brightness model estimated whether participants' slopes predicting unpleasantness as a function of brightness intensity differed significantly from zero on average (i.e., intercepts) and whether this relationship was moderated by self-reported menstrual pain, somatic symptoms, and


bladder pain. Given that PSD was estimated alongside brightness in level 1 models (see Eq. 4), brightness slopes are controlled for PSD at each electrode site (i.e., the relationship of unpleasantness and brightness at average PSD). It is for this reason that brightness slopes vary across electrodes because each participant varied in their average PSD for each electrode. After correcting for multiple comparisons, the relationship between unpleasantness ratings and brightness intensity was positive on average across participants at Oz (see Table 4) and across all electrode sites (see Supplementary Table 2), suggesting that participants experienced a monotonic increase in unpleasantness with each increasing brightness intensity (see Figure 4b). More specifically, at average intensities of menstrual pain, bladder pain, and somatic symptoms, the participants reported an increase of .36 [.23, .49] GBS points per increasing intensity level of brightness ( $p < .001$ ), or nearly 2 GBS points from the least to greatest intensity of brightness ( $\eta_p^2 = .17$ ).

The relationship between unpleasantness and brightness was moderated by participants' self-reported menstrual pain at Oz ( $\eta_p^2 = .03$ ) and additional exploratory sites including left posterior, right parietal, and left frontal electrodes ( $\eta_p^2 = .03-.06$ ). Increases in menstrual pain strengthened the positive relationship (i.e., steeper slopes) between unpleasantness ratings and brightness intensities (see Figure 5). In other words, participants with the greatest menstrual pain experienced more unpleasantness at equivalent intensities of brightness compared to those with less menstrual pain (see Supplementary Figure 1).

Somatic symptoms moderated the relationship between unpleasantness and brightness at a left frontal electrode (Fp1;  $\eta_p^2 = .03$ ,  $p = .048$ ) and a right posterior parietal site (P8,  $\eta_p^2 = .04$ ,  $p = .01$ ). A right posterior parietal site (CP6) was significant even after corrections for multiple comparisons ( $\eta_p^2 = .09$ ,  $p_{\text{fdr}} = .008$ ). Given its negative slope, this finding suggests that increases

in somatic symptoms are associated with an increased negative relationship between unpleasantness ratings and brightness intensities.

Although average unpleasantness ratings were moderated by bladder pain in the intercept model (Figure 4a), the relationship between brightness intensity and unpleasantness was not significantly moderated by bladder pain at any electrode sites ( $p > .2$ ).



**Figure 5. Bladder pain, somatic symptoms, and menstrual pain moderate the relationship between unpleasantness and brightness/PSD.** Scalp topographies of moderating slopes from second level multilevel modeling results. Given that positive relationships were observed between unpleasantness ratings and brightness/PSD (see Figure 4b), positive slopes here depict an increasing positive relationship between moderating variables, while negative slopes depict an increasing negative relationship. Menstrual pain ratings moderated the positive relationship between unpleasantness ratings and brightness, but not 25 Hz PSD at Oz (*a priori* chosen) and several other exploratory electrode sites. Somatic symptoms did not moderate these relationships at Oz; however, somatic symptoms moderated brightness and PSD slopes at a right posterior site (CP6;  $p_{fdr} < .05$  corrected), despite conflicting directions of moderation. In contrast, bladder pain moderated the positive relationship between unpleasantness and PSD, but not brightness. PSD = power spectral density.

### PSD Model


The PSD model estimated unpleasantness as a function of 25Hz PSD (i.e., evoked cortical excitability). Simultaneously, this model also evaluated whether this relationship was

moderated by self-reported menstrual pain, somatic symptoms, and experimentally evoked bladder pain. After correcting for multiple comparisons, the relationship between unpleasantness ratings and PSD was positive on average across participants at Oz (see Table 4) and several other central and right parieto-temporal sites (see Supplementary Table 2), suggesting participants experienced a monotonic increase in unpleasantness with increases in 25Hz SSVEP PSD (see Figure 4b). More specifically, the participants reported an increase of .11 [.04, .17] GBS points per increase in 1 dB of 25Hz power at Oz ( $p = .002$ ), or nearly 1.1 GBS points per 10 dB PSD increase in our observed SSVEP ( $\eta_p^2 = .07$ ). Thus, the relative amount of evoked activity at Oz, even accounting for simulation intensity, is a key predictor of evoked unpleasantness.

To determine whether bladder pain specifically moderated the cortical contribution to visual unpleasantness, we examined relationships in a final set of models controlling for menstrual pain and bladder pain (Figure 5). Although menstrual pain did not moderate this relationship, somatic symptoms did. Somatic symptoms demonstrated conflicting moderating effects on PSD slopes at two parietal electrode sites that survived corrections for multiple comparisons: relationships were both positive (CP6,  $\eta_p^2 = .08$ ,  $p_{fdr} = .015$ ) and negative (CP1,  $\eta_p^2 = .06$ ,  $p_{fdr} = .043$ ). We are cautious about interpreting these effects further given that electrode CP6, an electrode that was not defined *a priori*, negatively moderated brightness slopes (see above) but positively moderated PSD slopes. However, given that electrode CP6 survived multiple comparison corrections in both brightness (see above) and PSD models, we believe this right lateralized effect may represent a cortical phenomenon that differentially responds to brightness and cortical excitability independently of each other.

In the final moderation analysis, we observed that bladder pain positively moderated this relationship, suggesting that women with elevated bladder pain had a stronger positive

relationship between unpleasantness and cortical excitability at Oz ( $\eta_p^2 = .03$ ). In other words, women with increased bladder pain reported greater unpleasantness ratings at equivalent amounts of cortical response in primary visual cortex (see Supplementary Figure 1).



*Supplementary Figure 1. Partial regression (added variable) scatter plots depicting the moderating relationship between (a) menstrual pain and brightness slopes  $b_1$  and (b) bladder pain and PSD slopes ( $b_2$ ) at electrode Oz. These plots depict the unique relationship between the moderating variable (x-axis) and the dependent variable (y-axis) after accounting for the other predictors in the second level models. PSD = power spectral density (25Hz).*

### Discussion

These findings provide new insights regarding the neural correlates for multisensory hypersensitivity (MSH), which refers to persistent discomfort across multiple sensory modalities, in a cohort of women at heightened risk for chronic pelvic pain. Bladder pain report predicted visual unpleasantness, consistent with the hypothesis that MSH encompasses visceral sensation. We observed a positive relationship between perceived visual unpleasantness and cortical excitability, suggesting that excitability of primary visual cortex, as well as other cortical areas,

contributes to increased visual discomfort. Importantly, this relationship was moderated by participants' rating of bladder pain when accounting for somatic symptoms and menstrual pain; at equivalent primary visual cortex excitability, women with increased visceral sensitivity experienced increased visual discomfort. In other words, the increased visual unpleasantness in individuals exhibiting MSH is not driven by primary visual cortex hyperexcitability. Thus, we theorize that mechanisms in association cortex are responsible for amplifying signals from primary sensory cortex (e.g., visual cortex), resulting in the broad symptoms of MSH and chronic pain vulnerability.

### **Bladder Pain Predicts Visual Discomfort**

Participants with greater bladder pain rated the visual stimulation as more unpleasant, even after accounting for menstrual pain intensity and somatic symptom profile. This finding demonstrates MSH in this cohort across disparate sensory modalities: visceral and visual. Although visual stimulation is associated with increased unpleasantness in other conditions, like migraine (see Demarquay & Mauguière, 2016) and fibromyalgia (Harte et al., 2016), our study specifically identifies bladder pain as an additional marker correlated with MSH. Menstrual and somatic symptoms did not contribute to visual sensitivity, suggesting that only bladder pain was an indicator of MSH in the present study. Experimental bladder pain is also correlated with the severity of self-reported bladder pain, bowel pain, and intercourse pain in this cohort (Hellman et al., 2020) and in participants with severe chronic pain (Tu et al., 2017). We therefore surmise that bladder pain is a prominent dimension of MSH.

### **Cortical Excitability Predicts Visual Discomfort**


We observed a robust brain-behavior relationship that further established the role of cortical excitability in perceived visual unpleasantness. The participants' perceived unpleasantness to

visual stimulation was positively associated with cortical excitability across the entire scalp. Increased unpleasantness was also associated with increased visual stimulation brightness intensity, albeit seen across fewer electrode locations. These findings replicate previous investigations that demonstrated associations between unpleasantness and increased cortical excitability/activity in response to aversive visual stimulation (Adjajian et al., 2004; Haigh et al., 2013; Huang et al., 2011; Patterson Gentile & Aguirre, 2020). Our visual task showed that SSVEPs, a measure of cortical excitability, were effectively modulated and related to self-reported measures of unpleasantness, thus promoting the use of SSVEPs conducive to the study of MSH. Although conflicting associations between unpleasantness and cortical excitability were also previously reported (O'Hare, 2017), this discrepancy likely arises due to mechanistic differences in how visual stimulus manipulations, such as brightness and spatial frequency (e.g., gratings), are perceived and interpreted in the brain. Our study supports evidence that increased unpleasantness to a stimulus can be mediated by an increase in sensory pathway excitability (Curatolo et al., 2006), even in a non-somatic pathway such as vision.

### **Bladder pain moderates the brain-behavior relationship at Oz**

The robust association between visual unpleasantness and cortical excitability was positively moderated by bladder pain. A steeper positive relationship between unpleasantness and cortical excitability was observed in women with greater bladder pain (see Figure 6). This moderation accounted for variance associated with menstrual pain and somatic symptoms, providing evidence that bladder provocation was the predominant factor associated with MSH. Moreover, this effect was observed in our *a priori* electrode of interest Oz, where SSVEP amplitudes are generally observed and likely arise from primary visual cortex (V1) and motion sensitive visual cortex (V5/MT) (Norcia et al., 2015; Vialatte et al., 2010). At average primary

visual cortex excitability, women with greater bladder pain experienced more visual discomfort than women with less bladder pain. Otherwise stated, at low cortical excitability there were only slight differences in visual unpleasantness, while these differences were more pronounced at increased brightness intensities, with more unpleasantness experienced by women with greater bladder pain.



**Figure 6. Visceral sensitivity predicts increased visual unpleasantness at equivalent excitation of primary visual cortex.** Conceptual line plots demonstrating the moderating effect of bladder pain on the relationship between unpleasantness ratings and cortical excitability measured via 25Hz power spectral density (PSD) estimates (i.e., SSVEP amplitudes) at electrode Oz. This moderating effect implies that when visual cortex is minimally excited by visual stimulation, bladder pain has minimal effect on perceived unpleasantness. However, individuals with greater bladder pain report more unpleasantness when cortical excitability is high. Primary visual cortical excitability is not greater in individuals with heightened bladder pain; rather, downstream interpretation of this signal is likely amplified in women with greater bladder pain.

This finding implies that primary visual cortical excitability is not greater in individuals with heightened bladder pain; rather, downstream interpretation of this signal is likely amplified in women with greater bladder pain. Harte and colleagues (2016) similarly observed increased insular activation in response to aversive visual stimulation related to pain intensity in fibromyalgia, suggesting the insular cortex as a downstream target for integrative processing and sensory amplification. López-Solà and colleagues (2014) also observed this amplification in insular cortex and downstream cortical areas; however, concomitant reductions in primary visual



and auditory cortex activity were observed in fibromyalgia patients. In chronic pain conditions, altered neural processing in primary cortex, both hypoactivations (López-Solà et al., 2014) and hyperactivations (Lang et al., 2004; Montoya et al., 2006), is commonly observed (Apkarian et al., 2005). We provide contrasting evidence that primary visual cortex is not hyperexcitable in a cohort of women with varying menstrual and bladder pain comorbidity. This discrepancy may emerge from the millisecond temporal resolution of EEG that is methodologically suited to detect the short latency excitation (<50 ms) in primary cortices, unlike fMRI that typically averages signals over several seconds (Ghuman & Martin, 2019).

### **Somatic symptoms moderate brain-behavior relationships across parietal electrodes**

Electrode positions outside our *a priori* region of interest (Oz) did not demonstrate moderation effects between perceived unpleasantness and cortical excitability for either bladder or menstrual pain. Somatic symptoms, however, moderated this association across cortical sites putatively associated with non-specific widespread pain sensitivity. Although many different cortical regions could be responsible for these effects at the observed parietal electrode locations (CP6 and CP1), we can infer potential contributors. The 10-20 system of electrode placement positions CP6 above the angular gyrus (AG) corresponding to Brodmann area 39 (Pascual-Marqui, 1999; Pascual-Marqui et al., 1994). The AG has emerged as a major hub that integrates multisensory information to provide high-level interpretation of our environment (Seghier, 2013). Structurally, the AG is connected to frontotemporal cortex, medial temporal structures (e.g., hippocampus, parahippocampal gyrus), and the basal ganglia (e.g., caudate nucleus) (Seghier, 2013). Given that the visual task prompts participants to reflect on their experienced unpleasantness during stimulation, it is possible that the AG excitability may reflect this downstream contemplative process that integrates multisensory information with past

experiences (i.e., medial temporal lobe connections). An example of the AG and its potential multisensory relevance on widespread body symptoms was demonstrated in a study where AG activity was correlated with music-induced analgesia in fibromyalgia patients (Garza-Villarreal et al., 2015). In contrast, electrode CP1 is positioned near the left somatosensory association cortex and is less lateral and more dorsal than the AG. Somatosensory association cortex plays a vital role in deciphering the context of multimodal percepts and emotional processing. For instance, pairing a neutrally valenced visual stimulus with an aversive auditory stimulus resulted in increased negative emotional valence ratings and activation of somatosensory association cortex, even when the visual stimulus was not consciously perceived (Anders et al., 2004). We observed that somatic symptoms moderated relationships in parietal regions in opposite directions across the left and right hemispheres. Neuropsychological models of emotional processing have similarly differentiated valence (pleasant/unpleasant) and arousal (high/low), with unpleasantness and high arousal associated with greater right hemisphere involvement (Heller et al., 1997; Heller & Nitschke, 1998). Given that MSH is a predictor for chronic pain, it would be valuable to establish whether altered activity in parietal cortex also has predictive value.

### **Limitations**

Some study limitations may qualify our interpretations of the results and generalizability. First, the initial power analysis to plan the broader clinical trial (Hellman et al., 2020) did not account for the present investigation (i.e., *post hoc* aim). Despite this, our sample size ( $n = 147$ ) at an  $\alpha = .05$ , was well powered ( $> 99\%$ ) to detect a linear increase in SSVEP amplitude at Oz across brightness intensity ( $\eta_p^2 = .78$ ) and sufficiently powered (80%) to detect a small-to-medium effect ( $\eta_p^2 = .051$ ). This sample comprised a cohort of women with comorbid menstrual

and bladder pain sensitivity that places them at risk for developing chronic pain. These results should be verified in a cohort of severe chronic pain participants and in a comparable risk-enhanced male cohort to assess generalizability across sex.

Second, our study of MSH established a link between specific visceral components (i.e., bladder not uterus) and a disparate non-nociceptive sensory processing modality (i.e., vision). Although we have identified a relationship between bladder pain and other nociceptive modalities, such as pressure and cold pain sensitivity (Hellman et al., 2020), other sensory components were not experimentally measured, such as auditory and olfactory sensitivity. Future studies would be well served to assess how the presence of visceral sensitivity influences responses at other sensory modalities to broaden our mechanistic understanding of MSH. Third, EEG analyzed with SSVEPs limited our ability to resolve the contribution from subcortical sources (e.g., limbic system, insula), especially given our 32-channel montage. We encourage future studies to employ higher-density EEG methods in conjunction with similar task-evoked steady-state methods to increase source localization specificity.

A key strength of EEG is that it allows for objective temporal measurement of early increased cortical excitability. Our adaptation of this steady-state method, combined with simultaneous behavioral evaluation of unpleasantness, allowed for experimentally controlled electrophysiological measurements of a stimulus intensity-response over a short time (~2.5 minutes), resulting in a robust small-to-medium effect size ( $\eta_p^2 = .065$ ). Prior research has mainly relied on questionnaires to evaluate MSH rather than experimental methods (Jones et al., 2006; Yavuz et al., 2013; Zincir et al., 2014), despite the susceptibility of behavioral ratings of discomfort to retrospective biases (Redelmeier & Kahneman, 1996). Given the visual task's relatively brief administration, other studies can readily extend our findings to clarify

pathophysiology through experimental evaluation of brain-behavior relationships in conjunction with questionnaire-based assessments. Given these advantages, the visual task is well suited for simultaneous neuromodulation strategies, such as transcranial magnetic or electric stimulation and neurofeedback (Kayiran et al., 2010; Neeb et al., 2019; Stokes & Lappin, 2010), that seek to reduce MSH and chronic pain.

### **Conclusion**

Our findings demonstrated MSH in a large cohort of women with comorbid menstrual and bladder pain sensitivity. Brain-behavior relationships between cortical excitability and visual discomfort were moderated by visceral and somatic sensitivity. These results suggest that MSH likely results from maladapted sensory input integration rather than hyperexcitability of sensory afferents in the primary cortex. This evidence emphasizes the need for effective interventions targeting how sensory information is cortically integrated. Mindfulness interventions that decrease general distress also affect top-down modulation (Berkovich-Ohana et al., 2012; Farb et al., 2007; Grant et al., 2011; Jacobs et al., 1996; Travis et al., 2010) and even reduce SSVEP amplitude (Schöne et al., 2018). A future enhanced mindfulness strategy combining simultaneous neurofeedback (Dunham et al., 2019) from the visual task itself could be used to reprogram the neural circuitry responsible for MSH. Similarly, a key next step is determining whether other extant chronic pain treatments—transcranial magnetic stimulation (Grisaru et al., 1998), anticonvulsants (Harte et al., 2016), or antidepressants (Sayar et al., 2005)—could reduce MSH and these associated neural mechanisms in at-risk patients. The paradigm presented here provides a useful experimental method to further evaluate MSH and its neural correlates in order to inform the development of future neuroscience-informed interventions for individuals with chronic pain.

**Acknowledgements**

The authors thank Dr. G.F. Gebhart for his sagacious advice and editorial assistance. They are grateful to Ellen Garrison and Nicole Steiner for technical assistance. This study was funded by the National Institute of Child and Human Development (R01HD098193) and the National Institute of Diabetes and Digestive and Kidney Diseases (R01DK100368).

### References

- Abrams, P., Cardozo, L., Fall, M., Griffiths, D., Rosier, P., Ulmsten, U., van Kerrebroeck, P., Victor, A., & Wein, A. (2002). The standardisation of terminology of lower urinary tract function: Report from the Standardisation Sub-committee of the International Continence Society. *American Journal of Obstetrics and Gynecology*, *187*(1), 116–126.
- Adjamian, P., Holliday, I. E., Barnes, G. R., Hillebrand, A., Hadjipapas, A., & Singh, K. D. (2004). Induced visual illusions and gamma oscillations in human primary visual cortex. *European Journal of Neuroscience*, *20*(2), 587–592. <https://doi.org/10.1111/j.1460-9568.2004.03495.x>
- Anders, S., Birbaumer, N., Sadowski, B., Erb, M., Mader, I., Grodd, W., & Lotze, M. (2004). Parietal somatosensory association cortex mediates affective blindsight. *Nature Neuroscience*, *7*(4), 339–340. <https://doi.org/10.1038/nn1213>
- Apkarian, A. V., Bushnell, M. C., Treede, R.-D., & Zubieta, J.-K. (2005). Human brain mechanisms of pain perception and regulation in health and disease. *European Journal of Pain*, *9*(4), 463–463. <https://doi.org/10.1016/j.ejpain.2004.11.001>
- Arendt-Nielsen, L., Morlion, B., Perrot, S., Dahan, A., Dickenson, A., Kress, H. G., Wells, C., Bouhassira, D., & Drewes, A. M. (2017). *Assessment and manifestation of central sensitisation across different chronic pain conditions*. 26.
- Bar-Shalita, T., Granovsky, Y., Parush, S., & Weissman-Fogel, I. (2019). Sensory Modulation Disorder (SMD) and Pain: A New Perspective. *Frontiers in Integrative Neuroscience*, *13*, 27. <https://doi.org/10.3389/fnint.2019.00027>

- Benjamini, Y., & Hochberg, Y. (1995). Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing. *Journal of the Royal Statistical Society: Series B (Methodological)*, *57*(1), 289–300. <https://doi.org/10.1111/j.2517-6161.1995.tb02031.x>
- Bennett, R. M. (1999). Emerging concepts in the neurobiology of chronic pain: Evidence of abnormal sensory processing in fibromyalgia. *Mayo Clinic Proceedings*, *74*(4), 385–398. <https://doi.org/10.4065/74.4.385>
- Ben-Sasson, A., Carter, A. S., & Briggs-Gowan, M. J. (2009). Sensory over-responsivity in elementary school: Prevalence and social-emotional correlates. *Journal of Abnormal Child Psychology*, *37*(5), 705–716. <https://doi.org/10.1007/s10802-008-9295-8>
- Berkovich-Ohana, A., Glicksohn, J., & Goldstein, A. (2012). Mindfulness-induced changes in gamma band activity—Implications for the default mode network, self-reference and attention. *Clinical Neurophysiology: Official Journal of the International Federation of Clinical Neurophysiology*, *123*(4), 700–710. <https://doi.org/10.1016/j.clinph.2011.07.048>
- Cohen, J. (1983). The Cost of Dichotomization. *Applied Psychological Measurement*, *7*(3), 249–253. <https://doi.org/10.1177/014662168300700301>
- Curatolo, M., Arendt-Nielsen, L., & Petersen-Felix, S. (2006). Central Hypersensitivity in Chronic Pain: Mechanisms and Clinical Implications. *Physical Medicine and Rehabilitation Clinics of North America*, *17*(2), 287–302. <https://doi.org/10.1016/j.pmr.2005.12.010>
- Curtin, J. (2018). *lmSupport: Support for Linear Models*. R package version 2.9.13. <https://CRAN.R-project.org/package=lmSupport>

- Delorme, A., & Makeig, S. (2004). EEGLAB: An open source toolbox for analysis of single-trial EEG dynamics including independent component analysis. *Journal of Neuroscience Methods*, *134*(1), 9–21. <https://doi.org/10.1016/j.jneumeth.2003.10.009>
- Demarquay, G., & Mauguière, F. (2016). Central Nervous System Underpinnings of Sensory Hypersensitivity in Migraine: Insights from Neuroimaging and Electrophysiological Studies. *Headache: The Journal of Head and Face Pain*, *56*(9), 1418–1438. <https://doi.org/10.1111/head.12651>
- Derogatis, L. R., & Melisaratos, N. (1983). The Brief Symptom Inventory: An introductory report. *Psychological Medicine*, *13*(3), 595–605.
- Di Russo, F., Pitzalis, S., Aprile, T., Spitoni, G., Patria, F., Stella, A., Spinelli, D., & Hillyard, S. A. (2007). Spatiotemporal analysis of the cortical sources of the steady-state visual evoked potential. *Human Brain Mapping*, *28*(4), 323–334. <https://doi.org/10.1002/hbm.20276>
- Dunham, C. M., Burger, A. L., Hileman, B. M., Chance, E. A., Hutchinson, A. E., Kohli, C. M., DeNiro, L., Tall, J. M., & Lisko, P. (2019). Brainwave Self-Regulation During Bispectral Index™ Neurofeedback in Trauma Center Nurses and Physicians After Receiving Mindfulness Instructions. *Frontiers in Psychology*, *10*, 2153. <https://doi.org/10.3389/fpsyg.2019.02153>
- Farb, N. A. S., Segal, Z. V., Mayberg, H., Bean, J., McKeon, D., Fatima, Z., & Anderson, A. K. (2007). Attending to the present: Mindfulness meditation reveals distinct neural modes of self-reference. *Social Cognitive and Affective Neuroscience*, *2*(4), 313–322. <https://doi.org/10.1093/scan/nsm030>



- Fishbain, D. A., Lewis, J. E., Gao, J., Cole, B., & Steele Rosomoff, R. (2009). Is Chronic Pain Associated With Somatization/Hypochondriasis? An Evidence-Based Structured Review. *Pain Practice*, 9(6), 449–467. <https://doi.org/10.1111/j.1533-2500.2009.00309.x>
- Galambos, A., Szabó, E., Nagy, Z., Édes, A. E., Kocsel, N., Juhász, G., & Kökönyei, G. (2019). A systematic review of structural and functional MRI studies on pain catastrophizing. *Journal of Pain Research*, Volume 12, 1155–1178. <https://doi.org/10.2147/JPR.S192246>
- Garza-Villarreal, E. A., Jiang, Z., Vuust, P., Alcauter, S., Vase, L., Pasaye, E. H., Cavazos-Rodriguez, R., Brattico, E., Jensen, T. S., & Barrios, F. A. (2015). Music reduces pain and increases resting state fMRI BOLD signal amplitude in the left angular gyrus in fibromyalgia patients. *Frontiers in Psychology*, 6, 1051. <https://doi.org/10.3389/fpsyg.2015.01051>
- Geisser, M. E., Glass, J. M., Rajcevska, L. D., Clauw, D. J., Williams, D. A., Kileny, P. R., & Gracely, R. H. (2008). A Psychophysical Study of Auditory and Pressure Sensitivity in Patients With Fibromyalgia and Healthy Controls. *The Journal of Pain*, 9(5), 417–422. <https://doi.org/10.1016/j.jpain.2007.12.006>
- Geisser, M. E., Robinson, M. E., Keefe, F. J., & Weiner, M. L. (1994). Catastrophizing, depression and the sensory, affective and evaluative aspects of chronic pain. *Pain*, 59(1), 79–83.
- Ghuman, A. S., & Martin, A. (2019). Dynamic Neural Representations: An Inferential Challenge for fMRI. *Trends in Cognitive Sciences*, 23(7), 534–536. <https://doi.org/10.1016/j.tics.2019.04.004>

- Gracely, R. H., & Kwilosz, D. M. (1988). The Descriptor Differential Scale: Applying psychophysical principles to clinical pain assessment: *Pain*, 35(3), 279–288.  
[https://doi.org/10.1016/0304-3959\(88\)90138-8](https://doi.org/10.1016/0304-3959(88)90138-8)
- Grant, J. A., Courtemanche, J., & Rainville, P. (2011). A non-elaborative mental stance and decoupling of executive and pain-related cortices predicts low pain sensitivity in Zen meditators. *Pain*, 152(1), 150–156. <https://doi.org/10.1016/j.pain.2010.10.006>
- Greenspan, J. D., Craft, R. M., LeResche, L., Arendt-Nielsen, L., Berkley, K. J., Fillingim, R. B., Gold, M. S., Holdcroft, A., Lautenbacher, S., Mayer, E. A., Mogil, J. S., Murphy, A. Z., Traub, R. J., & Consensus Working Group of the Sex, Gender, and Pain SIG of the IASP. (2007). Studying sex and gender differences in pain and analgesia: A consensus report. *Pain*, 132 Suppl 1, S26-45. <https://doi.org/10.1016/j.pain.2007.10.014>
- Grisaru, N., Amir, M., Cohen, H., & Kaplan, Z. (1998). Effect of transcranial magnetic stimulation in posttraumatic stress disorder: A preliminary study. *Biological Psychiatry*, 44(1), 52–55.
- Haigh, S. M., Barningham, L., Berntsen, M., Coutts, L. V., Hobbs, E. S. T., Irabor, J., Lever, E. M., Tang, P., & Wilkins, A. J. (2013). Discomfort and the cortical haemodynamic response to coloured gratings. *Vision Research*, 89, 47–53.  
<https://doi.org/10.1016/j.visres.2013.07.003>
- Harte, S. E., Ichesco, E., Hampson, J. P., Peltier, S. J., Schmidt-Wilcke, T., Clauw, D. J., & Harris, R. E. (2016). Pharmacologic attenuation of cross-modal sensory augmentation within the chronic pain insula: *PAIN*, 157(9), 1933–1945.  
<https://doi.org/10.1097/j.pain.0000000000000593>

- Heller, W., & Nitschke, J. B. (1998). The Puzzle of Regional Brain Activity in Depression and Anxiety: The Importance of Subtypes and Comorbidity. *Cognition & Emotion, 12*(3).
- Heller, W., Nitschke, J. B., & Lindsay, D. L. (1997). Neuropsychological Correlates of Arousal in Self-reported Emotion. *Cognition & Emotion, 11*(4), 383–402.  
<https://doi.org/10.1080/026999397379854>
- Hellman, K. M., Datta, A., Steiner, N. D., Kane Morlock, J. N., Garrison, E. F., Clauw, D. J., & Tu, F. F. (2018). Identification of experimental bladder sensitivity among dysmenorrhea sufferers. *American Journal of Obstetrics and Gynecology, 219*(1), 84.e1-84.e8.  
<https://doi.org/10.1016/j.ajog.2018.04.030>
- Hellman, K. M., Roth, G. E., Dillane, K. E., Garrison, E. F., Oladosu, F. A., Clauw, D. J., & Tu, F. F. (2020). Dysmenorrhea subtypes exhibit differential quantitative sensory assessment profiles: *PAIN, 161*(6), 1227–1236. <https://doi.org/10.1097/j.pain.0000000000001826>
- Hjermstad, M. J., Fayers, P. M., Haugen, D. F., Caraceni, A., Hanks, G. W., Loge, J. H., Fainsinger, R., Aass, N., Kaasa, S., & European Palliative Care Research Collaborative (EPCRC). (2011). Studies comparing Numerical Rating Scales, Verbal Rating Scales, and Visual Analogue Scales for assessment of pain intensity in adults: A systematic literature review. *Journal of Pain and Symptom Management, 41*(6), 1073–1093.  
<https://doi.org/10.1016/j.jpainsymman.2010.08.016>
- Hollins, M., Harper, D., Gallagher, S., Owings, E. W., Lim, P. F., Miller, V., Siddiqi, M. Q., & Maixner, W. (2009). Perceived intensity and unpleasantness of cutaneous and auditory stimuli: An evaluation of the generalized hypervigilance hypothesis: *Pain, 141*(3), 215–221. <https://doi.org/10.1016/j.pain.2008.10.003>

- Huang, J., Zong, X., Wilkins, A., Jenkins, B., Bozoki, A., & Cao, Y. (2011). FMRI evidence that precision ophthalmic tints reduce cortical hyperactivation in migraine. *Cephalalgia*, *31*(8), 925–936. <https://doi.org/10.1177/0333102411409076>
- Jacobs, G. D., Benson, H., & Friedman, R. (1996). Topographic EEG mapping of the relaxation response. *Biofeedback and Self-Regulation*, *21*(2), 121–129.
- Jones, R., Latinovic, R., Charlton, J., & Gulliford, M. (2006). Physical and psychological comorbidity in irritable bowel syndrome: A matched cohort study using the General Practice Research Database. *Alimentary Pharmacology & Therapeutics*, *24*(5), 879–886. <https://doi.org/10.1111/j.1365-2036.2006.03044.x>
- Judd, C. M., McClelland, G. H., & Ryan, C. S. (2017). *Data Analysis: A Model Comparison Approach to Regression, ANOVA, and Beyond* (Third Edition). Routledge.
- Kayiran, S., Dursun, E., Dursun, N., Ermutlu, N., & Karamürsel, S. (2010). Neurofeedback intervention in fibromyalgia syndrome; a randomized, controlled, rater blind clinical trial. *Applied Psychophysiology and Biofeedback*, *35*(4), 293–302. <https://doi.org/10.1007/s10484-010-9135-9>
- Kayser, J. (2009). *Current source density (CSD) interpolation using spherical splines—CSD Toolbox (Version 1.1)*. <http://psychophysiology.cpmc.columbia.edu/Software/CSDtoolbox>
- Kayser, J., & Tenke, C. E. (2006). Principal components analysis of Laplacian waveforms as a generic method for identifying ERP generator patterns: I. Evaluation with auditory oddball tasks. *Clinical Neurophysiology*, *117*(2), 348–368. <https://doi.org/10.1016/j.clinph.2005.08.034>

- Lang, E., Kaltenhauser, M., Neundorfer, B., & Seidler, S. (2004). Hyperexcitability of the primary somatosensory cortex in migraine—A magnetoencephalographic study. *Brain*, *127*, 2459–2469. <https://doi.org/10.1093/brain/awh295>
- Larsson, M. B. O., Tillisch, K., Craig, A. D., Engström, M., Labus, J., Naliboff, B., Lundberg, P., Ström, M., Mayer, E. A., & Walter, S. A. (2012). *Brain Responses to Visceral Stimuli Reflect Visceral Sensitivity Thresholds in Patients With Irritable Bowel Syndrome*. *142*(3), 13.
- López-Solà, M., Pujol, J., Wager, T. D., Garcia-Fontanals, A., Blanco-Hinojo, L., Garcia-Blanco, S., Poca-Dias, V., Harrison, B. J., Contreras-Rodríguez, O., Monfort, J., Garcia-Fructuoso, F., & Deus, J. (2014). Altered Functional Magnetic Resonance Imaging Responses to Nonpainful Sensory Stimulation in Fibromyalgia Patients: Brain Response to Nonpainful Multisensory Stimulation in Fibromyalgia. *Arthritis & Rheumatology*, *66*(11), 3200–3209. <https://doi.org/10.1002/art.38781>
- Makeig, S., Jung, T.-P., Bell, A. J., Ghahremani, D., & Sejnowski, T. J. (1997). Blind separation of auditory event-related brain responses into independent components. *Proceedings of the National Academy of Sciences*, *94*(20), 10979–10984. <https://doi.org/10.1073/pnas.94.20.10979>
- Martenson, M. E., Halawa, O. I., Tonsfeldt, K. J., Maxwell, C. A., Hammack, N., Mist, S. D., Pennesi, M. E., Bennett, R. M., Mauer, K. M., Jones, K. D., & Heinricher, M. M. (2016). A possible neural mechanism for photosensitivity in chronic pain: *PAIN*, *157*(4), 868–878. <https://doi.org/10.1097/j.pain.0000000000000450>

- McBeth, J., Macfarlane, G. J., Benjamin, S., & Silman, A. J. (2001). Features of somatization predict the onset of chronic widespread pain: Results of a large population-based study. *Arthritis & Rheumatism*, *44*(4), 940–946.
- Molholm, S., Murphy, J. W., Bates, J., Ridgway, E. M., & Foxe, J. J. (2020). Multisensory Audiovisual Processing in Children With a Sensory Processing Disorder (I): Behavioral and Electrophysiological Indices Under Speeded Response Conditions. *Frontiers in Integrative Neuroscience*, *14*, 4. <https://doi.org/10.3389/fnint.2020.00004>
- Montoya, P., Sitges, C., García-Herrera, M., Rodríguez-Cotes, A., Izquierdo, R., Truyols, M., & Collado, D. (2006). Reduced brain habituation to somatosensory stimulation in patients with fibromyalgia. *Arthritis & Rheumatism*, *54*(6), 1995–2003. <https://doi.org/10.1002/art.21910>
- Mullen, T. (2012). *CleanLine EEGLAB plugin*. Neuroimaging Informatics Tools and Resources Clearinghouse (NITRC).
- Neeb, L., Bayer, A., Bayer, K.-E., Farmer, A., Fiebach, J. B., Siegmund, B., & Volz, M. S. (2019). Transcranial direct current stimulation in inflammatory bowel disease patients modifies resting-state functional connectivity: A RCT. *Brain Stimulation*, *12*(4), 978–980. <https://doi.org/10.1016/j.brs.2019.03.001>
- Neuwirth, E. (2014). *RColorBrewer: ColorBrewer Palettes*. R package version 1.1-2. <https://CRAN.R-project.org/package=RColorBrewer>
- Norcia, A. M., Appelbaum, L. G., Ales, J. M., Cottreau, B. R., & Rossion, B. (2015). The steady-state visual evoked potential in vision research: A review. *Journal of Vision*, *15*(6), 4. <https://doi.org/10.1167/15.6.4>

- O'Hare, L. (2016). Steady-state VEP responses to uncomfortable stimuli. *The European Journal of Neuroscience*. <https://doi.org/10.1111/ejn.13479>
- O'Hare, L. (2017). Steady-state VEP responses to uncomfortable stimuli. *European Journal of Neuroscience*, 45(3), 410–422. <https://doi.org/10.1111/ejn.13479>
- Pascual-Marqui, R. D. (1999). *Review of Methods for Solving the EEG Inverse Problem*. 1(1), 13.
- Pascual-Marqui, R. D., Michel, C. M., & Lehmann, D. (1994). Low resolution electromagnetic tomography: A new method for localizing electrical activity in the brain. *International Journal of Psychophysiology: Official Journal of the International Organization of Psychophysiology*, 18(1), 49–65. [https://doi.org/10.1016/0167-8760\(84\)90014-x](https://doi.org/10.1016/0167-8760(84)90014-x)
- Patterson Gentile, C., & Aguirre, G. K. (2020). A neural correlate of visual discomfort from flicker. *Journal of Vision*, 20(7), 11. <https://doi.org/10.1167/jov.20.7.11>
- Payne, L. A., Rapkin, A., Seidman, L., Zeltzer, L., & Tsao, J. (2017). Experimental and procedural pain responses in primary dysmenorrhea: A systematic review. *Journal of Pain Research, Volume 10*, 2233–2246. <https://doi.org/10.2147/JPR.S143512>
- Pederson, T. L. (2019). *patchwork: The Composer of Plots*. R package version 1.0.0. <https://CRAN.R-project.org/package=patchwork>
- Petzke, F., Harris, R. E., Williams, D. M., Clauw, D. J., & Gracely, R. H. (2005). Differences in unpleasantness induced by experimental pressure pain between patients with fibromyalgia and healthy controls. *European Journal of Pain*, 9(3), 325–335. <https://doi.org/10.1016/j.ejpain.2004.09.001>
- Phillips, K., & Clauw, D. J. (2011). Central pain mechanisms in chronic pain states—Maybe it is all in their head. *Best Practice*, 14.

- Quartana, P. J., Campbell, C. M., & Edwards, R. R. (2009). Pain catastrophizing: A critical review. *Expert Review of Neurotherapeutics*, *9*(5), 745–758.  
<https://doi.org/10.1586/ern.09.34>
- R Core Team. (2020). *R: A language and environment for statistical computing*. R Foundation for Statistical Computing. Vienna, Austria. <https://www.R-project.org/>
- Redelmeier, D. A., & Kahneman, D. (1996). Patients' memories of painful medical treatments: Real-time and retrospective evaluations of two minimally invasive procedures. *Pain*, *66*(1), 3–8.
- Robinson, D., & Hayes, A. (2020). *broom: Convert Statistical Analysis Objects into Tidy Tibbles*. R package version 0.5.5. <https://CRAN.R-project.org/package=broom>
- Royston, P., Altman, D. G., & Sauerbrei, W. (2006). Dichotomizing continuous predictors in multiple regression: A bad idea. *Statistics in Medicine*, *25*(1), 127–141.  
<https://doi.org/10.1002/sim.2331>
- Sayar, K., Barsky, A. J., & Gulec, H. (2005). Does somatosensory amplification decrease with antidepressant treatment? *Psychosomatics*, *46*(4), 340–344.  
<https://doi.org/10.1176/appi.psy.46.4.340>
- Schöne, B., Gruber, T., Graetz, S., Bernhof, M., & Malinowski, P. (2018). Mindful breath awareness meditation facilitates efficiency gains in brain networks: A steady-state visually evoked potentials study. *Scientific Reports*, *8*(1), 13687.  
<https://doi.org/10.1038/s41598-018-32046-5>
- Schrepf, A., Williams, D. A., Gallop, R., Naliboff, B. D., Basu, N., Kaplan, C., Harper, D. E., Landis, J. R., Clemens, J. Q., Strachan, E., Griffith, J. W., Afari, N., Hassett, A., Pontari, M. A., Clauw, D. J., & Harte, S. E. (2018). Sensory sensitivity and symptom severity



- represent unique dimensions of chronic pain: A MAPP Research Network study. *PAIN*, *159*(10), 2002–2011. <https://doi.org/10.1097/j.pain.0000000000001299>
- Seghier, M. L. (2013). The Angular Gyrus: Multiple Functions and Multiple Subdivisions. *The Neuroscientist*, *19*(1), 43–61. <https://doi.org/10.1177/1073858412440596>
- Stokes, D. A., & Lappin, M. S. (2010). Neurofeedback and biofeedback with 37 migraineurs: A clinical outcome study. *Behavioral and Brain Functions: BBF*, *6*, 9. <https://doi.org/10.1186/1744-9081-6-9>
- Travis, F., Haaga, D. A. F., Hagelin, J., Tanner, M., Arenander, A., Nidich, S., Gaylord-King, C., Grosswald, S., Rainforth, M., & Schneider, R. H. (2010). A self-referential default brain state: Patterns of coherence, power, and eLORETA sources during eyes-closed rest and Transcendental Meditation practice. *Cognitive Processing*, *11*(1), 21–30. <https://doi.org/10.1007/s10339-009-0343-2>
- Tu, F. F., Datta, A., Atashroo, D., Senapati, S., Roth, G., Clauw, D. J., & Hellman, K. M. (2020). Clinical profile of comorbid dysmenorrhea and bladder sensitivity: A cross-sectional analysis. *American Journal of Obstetrics and Gynecology*, *222*(6), 594.e1-594.e11. <https://doi.org/10.1016/j.ajog.2019.12.010>
- Tu, F. F., Epstein, A. E., Pozolo, K. E., Sexton, D. L., Melnyk, A. I., & Hellman, K. M. (2013). A Noninvasive Bladder Sensory Test Supports a Role for Dysmenorrhea Increasing Bladder Noxious Mechanosensitivity: *The Clinical Journal of Pain*, *29*(10), 883–890. <https://doi.org/10.1097/AJP.0b013e31827a71a3>
- Tu, F. F., Kane, J. N., & Hellman, K. M. (2017). Noninvasive experimental bladder pain assessment in painful bladder syndrome. *BJOG: An International Journal of Obstetrics & Gynaecology*, *124*(2), 283–291. <https://doi.org/10.1111/1471-0528.14433>

- Vialatte, F.-B., Maurice, M., Dauwels, J., & Cichocki, A. (2010). Steady-state visually evoked potentials: Focus on essential paradigms and future perspectives. *Progress in Neurobiology*, *90*(4), 418–438. <https://doi.org/10.1016/j.pneurobio.2009.11.005>
- Westling, A. M., Tu, F. F., Griffith, J. W., & Hellman, K. M. (2013). The association of dysmenorrhea with noncyclic pelvic pain accounting for psychological factors. *American Journal of Obstetrics and Gynecology*, *209*(5), 422.e1-422.e10. <https://doi.org/10.1016/j.ajog.2013.08.020>
- Wickham, H. (2016). *ggplot2: Elegant Graphics for Data Analysis*. Springer-Verlag.
- Wickham, H., François, R., Henry, L., & Müller, K. (2020). *dplyr: A Grammar of Data Manipulation*. R package version 0.8.5. <https://CRAN.R-project.org/package=dplyr>
- Winkler, I., Haufe, S., & Tangermann, M. (2011). Automatic Classification of Artifactual ICA-Components for Artifact Removal in EEG Signals. *Behavioral and Brain Functions*, *7*(1), 30. <https://doi.org/10.1186/1744-9081-7-30>
- Yarnitsky, D. (2010). Conditioned pain modulation (the diffuse noxious inhibitory control-like effect): Its relevance for acute and chronic pain states. *Current Opinion in Anesthesiology*, *23*(5), 611–615.
- Yavuz, B. G., Aydinlar, E. I., Dikmen, P. Y., & Incesu, C. (2013). Association between somatic amplification, anxiety, depression, stress and migraine. *The Journal of Headache and Pain*, *14*, 53. <https://doi.org/10.1186/1129-2377-14-53>
- Yee, C. M., Javitt, D. C., & Miller, G. A. (2015). Replacing DSM Categorical Analyses With Dimensional Analyses in Psychiatry Research: The Research Domain Criteria Initiative. *JAMA Psychiatry*, *72*(12), 1159–1160. <https://doi.org/10.1001/jamapsychiatry.2015.1900>

Zhu, D., Bieger, J., Garcia Molina, G., & Aarts, R. M. (2010). A Survey of Stimulation Methods Used in SSVEP-Based BCIs. *Computational Intelligence and Neuroscience*, 2010, 1–12.

<https://doi.org/10.1155/2010/702357>

Zincir, S. B., Sunbul, M., Sunbul, E. A., Dalkilic, B., Cengiz, F., Kivrak, T., & Durmus, E. (2014). Evaluation of alexithymia, somatosensory sensitivity, and health anxiety levels in patients with noncardiac chest pain. *BioMed Research International*, 2014, 896183.

<https://doi.org/10.1155/2014/896183>

Table 1.

*Participant Demographics.*

Measure	Response	N	% of N or M (SD)	Range
Age (years)		147	24.1 (6.3)	18-43
Race	White	87	59.2%	
	Black or African American	13	8.8%	
	Asian	32	21.8%	
	Native Hawaiian or Pacific Islander	0	0.0%	
	American Indian or Alaskan Native	1	0.7%	
	Multi-Racial	13	8.8%	
	Did not respond	1	0.7%	
Ethnicity	Hispanic or Latino	23	15.6%	
	Not Hispanic or Latino	124	84.4%	
Average number of days bleeding <sup>#</sup>		146	5.7 (1.3)	3-10
<u>Questions for participants with painful periods only:</u>		116	78.9%	
Did period pain start at the time of menarche? *	Yes	60	51.7%	
Age (years) that painful periods began (if not at menarche)?		56	16.3 (2.9)	10-28
Years since menarche (first period) without a period? *	Never, always had a regular period	67	57.8%	
	Less than 1 year	32	27.6%	
	1	8	6.9%	
	2	3	2.6%	
	3	2	1.7%	
	5 to 10	3	2.6%	
	More than ten years	1	0.9%	
Days of pelvic menstrual pain/month *		116	3.7 (2.0)	1-10
Days of school or work missed in last 3 months *		116	2.2 (3.3)	0-25

*Note.* \* participants were administered this question if they answered Yes to painful periods (> 5 out of 10); # one participant was not administered this question because she did not report having a period for the last 6 months due to birth control pill use although she

had a period before the EEG visit.

Table 2.

*Regression Results: Predicting Power Spectral Density as a Function of Increasing Brightness at Electrode Oz*

Electrode	Source	<i>b</i>	95% CI		<i>SE</i>	<i>SS</i>	<i>MSE</i>	<i>F</i>	$\eta_p^2$
			<i>LL</i>	<i>UL</i>					
Oz	Intercept	-23.76	-24.68	-22.84	0.47	82992.47	31.92	2600.06	0.95
Oz	Brightness	2.05	1.87	2.23	0.09	617.64	1.22	504.68	0.78

*Note.* Both FDR corrected and uncorrected *p* values were < .001; *df* for the numerator and denominator were 1 and 146, respectively; LL = lower level; UL = upper level.

Table 3.

*Correlations and Descriptive Statistics of Moderating Variables: Somatic Symptoms and Pain*

Variable 1	Variable 2	<i>r</i>	Bootstrapped 95% CI			Variable 1 Descriptive Statistics				
			Lower Level	Upper Level	<i>p</i>	<i>M</i>	<i>SD</i>	<i>SEM</i>	<i>MIN</i>	<i>MAX</i>
Menstrual Pain	Bladder Pain	0.28	0.13	0.42	< .001	62.5	26.1	2.15	0	100
Pain at First Urge	BSI Total Score	0.28	-0.002	0.31	<.001	12.2	16	1.32	0	59
BSI Total Score	Menstrual Pain	0.16	0.12	0.42	.053	2.37	2.4	0.198	0	15

Table 4.

*Regression Results for Second Level Models Estimating Brain-Behavior Relationships and the Moderating Effects of Pain and Somatic Symptoms at Electrode Oz.*

Model	Source	<i>b</i>	95% CI		<i>SE</i>	<i>SS</i>	<i>MSE</i>	<i>F</i>	<i>p</i>	$\eta_p^2$
			<i>LL</i>	<i>UL</i>						
Intercept	Intercept	7.997	7.367	8.627	0.319	9401.60	14.9	630.0	< .001	.815
Intercept	Menstrual Pain	0.012	-0.013	0.038	0.013	13.99	14.9	0.9	.335	.007
Intercept	Somatic Symptoms	-0.135	-0.411	0.140	0.139	14.13	14.9	0.9	.332	.007
Intercept	Bladder Pain	0.064	0.022	0.107	0.021	134.33	14.9	9.0	.003	.059
Brightness	Intercept	0.357	0.225	0.489	0.067	18.75	0.7	28.6	< .001	.167
Brightness	Menstrual Pain	0.006	0.001	0.011	0.003	3.32	0.7	5.1	.026	.034
Brightness	Somatic Symptoms	-0.032	-0.090	0.025	0.029	0.80	0.7	1.2	.271	.008
Brightness	Bladder Pain	-0.003	-0.012	0.006	0.004	0.27	0.7	0.4	.519	.003
PSD	Intercept	0.107	0.040	0.174	0.034	1.68	0.2	9.9	.002	.065
PSD	Menstrual Pain	-0.001	-0.004	0.002	0.001	0.12	0.2	0.7	.404	.005
PSD	Somatic Symptoms	-0.005	-0.034	0.025	0.015	0.02	0.2	0.1	.750	.001
PSD	Bladder Pain	0.005	0.001	0.010	0.002	0.83	0.2	4.9	.029	.033

*Note.* *df* for the numerator and denominator were 1 and 143, respectively; LL = lower level; UL = upper level.



## Supplementary Table 1.

*Regression Results: Predicting Power Spectral Density as a Function of Increasing Brightness**Across All Electrodes*

Electrode	Source	<i>b</i>	95% CI		<i>SE</i>	<i>SS</i>	<i>MSE</i>	<i>F</i>	$\eta_p^2$
			<i>LL</i>	<i>UL</i>					
C3	Intercept	-33.05	-33.74	-32.35	0.35	160549.52	18.14	8849.72	0.98
C3	Brightness	0.30	0.21	0.40	0.05	13.56	0.35	38.94	0.21
C4	Intercept	-32.93	-33.64	-32.21	0.36	159368.39	19.08	8350.83	0.98
C4	Brightness	0.40	0.29	0.51	0.05	23.71	0.43	55.05	0.27
CP1	Intercept	-31.87	-32.39	-31.35	0.26	149306.67	10.31	14478.54	0.99
CP1	Brightness	0.84	0.73	0.95	0.06	103.96	0.48	217.22	0.60
CP2	Intercept	-32.02	-32.53	-31.51	0.26	150694.86	9.81	15358.13	0.99
CP2	Brightness	0.79	0.68	0.89	0.05	90.88	0.42	215.55	0.60
CP5	Intercept	-32.39	-33.03	-31.74	0.32	154180.99	15.52	9934.66	0.99
CP5	Brightness	0.82	0.68	0.95	0.07	98.07	0.67	145.77	0.50
CP6	Intercept	-31.35	-32.10	-30.59	0.38	144443.06	21.31	6777.57	0.98
CP6	Brightness	1.13	0.99	1.27	0.07	187.01	0.74	252.54	0.63
Cz	Intercept	-31.58	-32.14	-31.02	0.28	146617.93	11.77	12453.33	0.99
Cz	Brightness	0.59	0.47	0.70	0.06	50.42	0.47	107.91	0.42
F3	Intercept	-33.44	-34.10	-32.78	0.33	164362.99	16.48	9971.85	0.99
F3	Brightness	0.28	0.19	0.37	0.04	11.52	0.27	42.04	0.22
F4	Intercept	-33.55	-34.20	-32.90	0.33	165465.80	16.06	10305.60	0.99
F4	Brightness	0.37	0.28	0.47	0.05	20.66	0.31	67.19	0.32

F7	Intercept	-33.60	-34.21	-32.99	0.31	165957.25	13.81	12021.46	0.99
F7	Brightness	0.46	0.36	0.56	0.05	30.84	0.37	82.58	0.36
F8	Intercept	-33.94	-34.52	-33.36	0.29	169314.79	12.64	13394.94	0.99
F8	Brightness	0.45	0.36	0.54	0.05	30.15	0.30	98.95	0.40
FC1	Intercept	-33.15	-33.64	-32.67	0.25	161586.36	8.96	18026.62	0.99
FC1	Brightness	0.30	0.21	0.38	0.04	13.00	0.27	48.78	0.25
FC2	Intercept	-33.42	-33.98	-32.87	0.28	164216.73	11.70	14037.12	0.99
FC2	Brightness	0.38	0.30	0.47	0.04	21.32	0.27	77.72	0.35
FC5	Intercept	-36.39	-37.06	-35.72	0.34	194656.75	16.69	11666.25	0.99
FC5	Brightness	0.43	0.33	0.52	0.05	26.58	0.31	86.56	0.37
FC6	Intercept	-35.96	-36.56	-35.36	0.30	190124.92	13.55	14028.22	0.99
FC6	Brightness	0.57	0.47	0.67	0.05	47.46	0.39	120.74	0.45
Fp1	Intercept	-33.59	-34.28	-32.91	0.34	165899.40	17.46	9500.04	0.98
Fp1	Brightness	0.71	0.59	0.83	0.06	73.90	0.56	132.13	0.48
Fp2	Intercept	-33.85	-34.51	-33.19	0.33	168419.31	16.37	10290.52	0.99
Fp2	Brightness	0.69	0.56	0.83	0.07	70.26	0.68	103.83	0.42
FT10	Intercept	-34.05	-34.57	-33.53	0.26	170412.26	10.19	16727.84	0.99
FT10	Brightness	0.61	0.49	0.73	0.06	54.89	0.51	108.27	0.43
FT9	Intercept	-33.19	-33.69	-32.69	0.26	161930.75	9.58	16900.83	0.99
FT9	Brightness	0.50	0.40	0.60	0.05	36.83	0.39	94.05	0.39
Fz	Intercept	-32.53	-32.99	-32.06	0.23	155525.37	8.06	19300.29	0.99
Fz	Brightness	0.29	0.21	0.37	0.04	12.23	0.24	50.19	0.26
O1	Intercept	-26.04	-26.83	-25.25	0.40	99674.02	23.37	4264.77	0.97

O1	Brightness	1.51	1.35	1.66	0.08	333.19	0.86	386.08	0.73
O2	Intercept	-25.24	-26.19	-24.28	0.48	93641.62	34.36	2725.20	0.95
O2	Brightness	1.74	1.57	1.91	0.09	446.71	1.09	410.68	0.74
Oz	Intercept	-23.76	-24.68	-22.84	0.47	82992.47	31.92	2600.06	0.95
Oz	Brightness	2.05	1.87	2.23	0.09	617.64	1.22	504.68	0.78
P3	Intercept	-28.91	-29.57	-28.26	0.33	122874.54	16.20	7583.54	0.98
P3	Brightness	1.08	0.93	1.22	0.07	170.46	0.82	207.32	0.59
P4	Intercept	-27.08	-27.83	-26.33	0.38	107831.97	21.16	5096.26	0.97
P4	Brightness	1.18	1.04	1.32	0.07	203.70	0.72	283.55	0.66
P7	Intercept	-28.41	-29.16	-27.66	0.38	118621.46	21.12	5617.08	0.97
P7	Brightness	1.40	1.25	1.56	0.08	289.50	0.87	331.65	0.69
P8	Intercept	-27.23	-28.02	-26.44	0.40	109028.88	23.47	4646.25	0.97
P8	Brightness	1.35	1.20	1.50	0.08	269.01	0.84	321.58	0.69
Pz	Intercept	-27.99	-28.68	-27.31	0.35	115184.29	17.76	6484.82	0.98
Pz	Brightness	0.99	0.83	1.14	0.08	143.36	0.89	160.59	0.52
T7	Intercept	-32.69	-33.35	-32.03	0.34	157068.91	16.51	9512.60	0.98
T7	Brightness	0.59	0.48	0.70	0.06	50.65	0.45	111.63	0.43
T8	Intercept	-33.08	-33.73	-32.42	0.33	160826.65	16.17	9946.21	0.99
T8	Brightness	0.81	0.68	0.93	0.06	95.44	0.62	155.18	0.52
TP10	Intercept	-30.83	-31.54	-30.11	0.36	139682.32	19.46	7178.68	0.98
TP10	Brightness	1.26	1.11	1.42	0.08	233.98	0.91	258.47	0.64
TP9	Intercept	-31.11	-31.78	-30.43	0.34	142226.41	17.32	8213.65	0.98
TP9	Brightness	0.91	0.77	1.05	0.07	122.67	0.75	164.05	0.53

*Note.* Both FDR corrected and uncorrected  $p$  values were  $< .001$ ;  $df$  for the numerator and denominator were 1 and 46, respectively; LL = lower level; UL = upper level.

Supplementary Table 2.

*Electrode-wise Brain-Behavior Multilevel Modeling Results.*

Electrode	Model	Source	<i>b</i>	95% CI		<i>SE</i>	<i>SS</i>	<i>MSE</i>	<i>F</i>	<i>p</i>	<i>p<sub>fdr</sub></i>	$\eta_p^2$
				<i>LL</i>	<i>UL</i>							
All	Intercept	Intercept	7.997	7.367	8.627	0.319	9401.60	14.92	630.0	< .001	< .001	.815
All	Intercept	Bladder Pain	0.064	0.022	0.107	0.021	134.33	14.92	9.0	.003	.003	.059
All	Intercept	Menstrual Pain	0.012	-0.013	0.038	0.013	13.99	14.92	0.9	.335	.335	.007
All	Intercept	Somatic Symptoms	-0.135	-0.411	0.140	0.139	14.13	14.92	0.9	.332	.332	.007
C3	Brightness	Intercept	0.559	0.411	0.706	0.075	45.92	0.82	56.1	< .001	< .001	.282
C3	Brightness	Bladder Pain	0.000	-0.010	0.010	0.005	0.00	0.82	0.0	.985	.985	< .001
C3	Brightness	Menstrual Pain	0.005	-0.001	0.011	0.003	2.35	0.82	2.9	.093	.153	.02
C3	Brightness	Somatic Symptoms	-0.028	-0.093	0.036	0.033	0.61	0.82	0.7	.389	.817	.005
C4	Brightness	Intercept	0.451	0.297	0.606	0.078	29.96	0.90	33.4	< .001	< .001	.189
C4	Brightness	Bladder Pain	-0.005	-0.015	0.005	0.005	0.82	0.90	0.9	.34	.985	.006
C4	Brightness	Menstrual Pain	0.006	0.000	0.012	0.003	3.40	0.90	3.8	.054	.132	.026
C4	Brightness	Somatic Symptoms	-0.053	-0.121	0.014	0.034	2.18	0.90	2.4	.121	.58	.017
CP1	Brightness	Intercept	0.492	0.351	0.633	0.071	35.61	0.75	47.7	< .001	< .001	.25
CP1	Brightness	Bladder Pain	-0.002	-0.011	0.008	0.005	0.10	0.75	0.1	.717	.985	.001
CP1	Brightness	Menstrual Pain	0.005	-0.001	0.010	0.003	1.99	0.75	2.7	.105	.153	.018
CP1	Brightness	Somatic Symptoms	0.013	-0.048	0.075	0.031	0.14	0.75	0.2	.669	.93	.001
CP2	Brightness	Intercept	0.448	0.256	0.640	0.097	29.50	1.38	21.3	< .001	< .001	.13
CP2	Brightness	Bladder Pain	0.001	-0.012	0.014	0.007	0.01	1.38	0.0	.926	.985	< .001
CP2	Brightness	Menstrual Pain	0.008	0.001	0.016	0.004	6.26	1.38	4.5	.035	.126	.031
CP2	Brightness	Somatic Symptoms	-0.078	-0.162	0.006	0.042	4.71	1.38	3.4	.067	.535	.023
CP5	Brightness	Intercept	0.434	0.262	0.606	0.087	27.64	1.11	24.8	< .001	< .001	.148
CP5	Brightness	Bladder Pain	0.002	-0.010	0.013	0.006	0.09	1.11	0.1	.78	.985	.001
CP5	Brightness	Menstrual Pain	0.004	-0.003	0.011	0.004	1.55	1.11	1.4	.239	.278	.01
CP5	Brightness	Somatic Symptoms	-0.029	-0.104	0.046	0.038	0.64	1.11	0.6	.448	.843	.004
CP6	Brightness	Intercept	0.428	0.240	0.617	0.095	26.96	1.34	20.2	< .001	< .001	.124

CP6	Brightness	Bladder Pain	0.005	-0.007	0.018	0.006	0.96	1.34	0.7	.398	.985	.005
CP6	Brightness	Menstrual Pain	0.006	-0.001	0.014	0.004	3.71	1.34	2.8	.098	.153	.019
CP6	Brightness	Somatic Symptoms	-0.157	-0.239	-0.074	0.042	18.87	1.34	14.1	< .001	.008	.09
Cz	Brightness	Intercept	0.481	0.333	0.629	0.075	33.98	0.82	41.2	< .001	< .001	.224
Cz	Brightness	Bladder Pain	-0.002	-0.012	0.008	0.005	0.09	0.82	0.1	.747	.985	.001
Cz	Brightness	Menstrual Pain	0.004	-0.002	0.010	0.003	1.63	0.82	2.0	.162	.215	.014
Cz	Brightness	Somatic Symptoms	-0.018	-0.083	0.046	0.033	0.25	0.82	0.3	.579	.896	.002
F3	Brightness	Intercept	0.562	0.423	0.700	0.070	46.37	0.72	64.2	< .001	< .001	.31
F3	Brightness	Bladder Pain	-0.001	-0.010	0.009	0.005	0.01	0.72	0.0	.913	.985	< .001
F3	Brightness	Menstrual Pain	0.009	0.003	0.014	0.003	6.70	0.72	9.3	.003	.089	.061
F3	Brightness	Somatic Symptoms	-0.008	-0.068	0.053	0.031	0.04	0.72	0.1	.804	.934	< .001
F4	Brightness	Intercept	0.485	0.357	0.613	0.065	34.58	0.62	56.1	< .001	< .001	.282
F4	Brightness	Bladder Pain	0.002	-0.006	0.011	0.004	0.16	0.62	0.3	.61	.985	.002
F4	Brightness	Menstrual Pain	0.005	0.000	0.010	0.003	2.15	0.62	3.5	.064	.134	.024
F4	Brightness	Somatic Symptoms	-0.032	-0.088	0.024	0.028	0.79	0.62	1.3	.259	.723	.009
F7	Brightness	Intercept	0.515	0.363	0.667	0.077	39.00	0.87	44.7	< .001	< .001	.238
F7	Brightness	Bladder Pain	0.007	-0.004	0.017	0.005	1.43	0.87	1.6	.203	.985	.011
F7	Brightness	Menstrual Pain	0.004	-0.002	0.010	0.003	1.40	0.87	1.6	.208	.266	.011
F7	Brightness	Somatic Symptoms	-0.016	-0.083	0.051	0.034	0.20	0.87	0.2	.635	.924	.002
F8	Brightness	Intercept	0.450	0.309	0.590	0.071	29.75	0.74	40.0	< .001	< .001	.219
F8	Brightness	Bladder Pain	0.003	-0.006	0.013	0.005	0.37	0.74	0.5	.484	.985	.003
F8	Brightness	Menstrual Pain	0.002	-0.003	0.008	0.003	0.55	0.74	0.7	.392	.433	.005
F8	Brightness	Somatic Symptoms	0.006	-0.056	0.067	0.031	0.03	0.74	0.0	.85	.934	< .001
FC1	Brightness	Intercept	0.685	0.490	0.879	0.098	68.91	1.42	48.5	< .001	< .001	.253
FC1	Brightness	Bladder Pain	0.007	-0.006	0.020	0.007	1.62	1.42	1.1	.288	.985	.008
FC1	Brightness	Menstrual Pain	0.008	0.001	0.016	0.004	6.40	1.42	4.5	.036	.126	.031
FC1	Brightness	Somatic Symptoms	-0.006	-0.091	0.079	0.043	0.03	1.42	0.0	.886	.934	< .001
FC2	Brightness	Intercept	0.526	0.386	0.666	0.071	40.72	0.74	55.2	< .001	< .001	.278
FC2	Brightness	Bladder Pain	0.003	-0.007	0.012	0.005	0.22	0.74	0.3	.585	.985	.002
FC2	Brightness	Menstrual Pain	0.003	-0.002	0.009	0.003	1.08	0.74	1.5	.228	.278	.01
FC2	Brightness	Somatic Symptoms	-0.010	-0.071	0.052	0.031	0.07	0.74	0.1	.756	.934	.001

FC5	Brightness	Intercept	0.479	0.349	0.608	0.065	33.69	0.63	53.6	< .001	< .001	.273
FC5	Brightness	Bladder Pain	0.002	-0.007	0.011	0.004	0.13	0.63	0.2	.654	.985	.001
FC5	Brightness	Menstrual Pain	0.004	-0.001	0.010	0.003	1.68	0.63	2.7	.104	.153	.018
FC5	Brightness	Somatic Symptoms	-0.018	-0.075	0.038	0.029	0.26	0.63	0.4	.519	.896	.003
FC6	Brightness	Intercept	0.527	0.394	0.660	0.067	40.86	0.67	61.4	< .001	< .001	.3
FC6	Brightness	Bladder Pain	0.001	-0.008	0.010	0.005	0.05	0.67	0.1	.789	.985	.001
FC6	Brightness	Menstrual Pain	0.002	-0.004	0.007	0.003	0.22	0.67	0.3	.565	.583	.002
FC6	Brightness	Somatic Symptoms	-0.016	-0.074	0.042	0.029	0.20	0.67	0.3	.588	.896	.002
Fp1	Brightness	Intercept	0.524	0.361	0.688	0.083	40.43	1.01	40.1	< .001	< .001	.219
Fp1	Brightness	Bladder Pain	0.001	-0.010	0.012	0.006	0.03	1.01	0.0	.863	.985	< .001
Fp1	Brightness	Menstrual Pain	0.008	0.001	0.015	0.003	5.82	1.01	5.8	.018	.113	.039
Fp1	Brightness	Somatic Symptoms	-0.072	-0.144	-0.001	0.036	4.01	1.01	4.0	.048	.514	.027
Fp2	Brightness	Intercept	0.428	0.279	0.578	0.076	26.98	0.84	32.0	< .001	< .001	.183
Fp2	Brightness	Bladder Pain	0.004	-0.006	0.014	0.005	0.44	0.84	0.5	.474	.985	.004
Fp2	Brightness	Menstrual Pain	0.004	-0.002	0.010	0.003	1.76	0.84	2.1	.151	.211	.014
Fp2	Brightness	Somatic Symptoms	-0.011	-0.077	0.054	0.033	0.10	0.84	0.1	.732	.934	.001
FT10	Brightness	Intercept	0.451	0.302	0.600	0.076	29.93	0.84	35.7	< .001	< .001	.2
FT10	Brightness	Bladder Pain	0.005	-0.005	0.015	0.005	0.87	0.84	1.0	.31	.985	.007
FT10	Brightness	Menstrual Pain	0.005	-0.001	0.011	0.003	2.29	0.84	2.7	.1	.153	.019
FT10	Brightness	Somatic Symptoms	0.002	-0.063	0.067	0.033	0.00	0.84	0.0	.955	.955	< .001
FT9	Brightness	Intercept	0.542	0.402	0.682	0.071	43.16	0.74	58.3	< .001	< .001	.289
FT9	Brightness	Bladder Pain	0.003	-0.006	0.013	0.005	0.32	0.74	0.4	.512	.985	.003
FT9	Brightness	Menstrual Pain	0.006	0.000	0.012	0.003	3.20	0.74	4.3	.039	.126	.029
FT9	Brightness	Somatic Symptoms	-0.046	-0.107	0.015	0.031	1.64	0.74	2.2	.139	.58	.015
Fz	Brightness	Intercept	0.515	0.373	0.657	0.072	39.02	0.76	51.5	< .001	< .001	.265
Fz	Brightness	Bladder Pain	0.005	-0.005	0.014	0.005	0.67	0.76	0.9	.35	.985	.006
Fz	Brightness	Menstrual Pain	0.006	0.000	0.011	0.003	2.90	0.76	3.8	.052	.132	.026
Fz	Brightness	Somatic Symptoms	-0.029	-0.091	0.033	0.031	0.67	0.76	0.9	.35	.817	.006
O1	Brightness	Intercept	0.459	0.301	0.618	0.080	31.03	0.95	32.7	< .001	< .001	.186
O1	Brightness	Bladder Pain	-0.001	-0.011	0.010	0.005	0.01	0.95	0.0	.905	.985	.
O1	Brightness	Menstrual Pain	0.008	0.002	0.015	0.003	6.42	0.95	6.8	.01	.109	.045

O1	Brightness	Somatic Symptoms	-0.059	-0.129	0.010	0.035	2.69	0.95	2.8	.094	.58	.019
O2	Brightness	Intercept	0.410	0.258	0.562	0.077	24.69	0.87	28.4	< .001	< .001	.166
O2	Brightness	Bladder Pain	0.005	-0.005	0.016	0.005	0.94	0.87	1.1	.3	.985	.008
O2	Brightness	Menstrual Pain	0.004	-0.002	0.010	0.003	1.19	0.87	1.4	.243	.278	.01
O2	Brightness	Somatic Symptoms	-0.031	-0.097	0.036	0.034	0.74	0.87	0.8	.359	.817	.006
Oz	Brightness	Intercept	0.357	0.225	0.489	0.067	18.75	0.66	28.6	< .001	< .001	.167
Oz	Brightness	Bladder Pain	-0.003	-0.012	0.006	0.004	0.27	0.66	0.4	.519	.985	.003
Oz	Brightness	Menstrual Pain	0.006	0.001	0.011	0.003	3.32	0.66	5.1	.026	.118	.034
Oz	Brightness	Somatic Symptoms	-0.032	-0.090	0.025	0.029	0.80	0.66	1.2	.271	.723	.008
P3	Brightness	Intercept	0.453	0.305	0.601	0.075	30.18	0.82	36.7	< .001	< .001	.204
P3	Brightness	Bladder Pain	0.000	-0.010	0.010	0.005	0.01	0.82	0.0	.933	.985	< .001
P3	Brightness	Menstrual Pain	0.006	0.000	0.012	0.003	3.22	0.82	3.9	.05	.132	.027
P3	Brightness	Somatic Symptoms	-0.042	-0.106	0.023	0.033	1.35	0.82	1.6	.202	.718	.011
P4	Brightness	Intercept	0.481	0.345	0.616	0.069	34.01	0.69	49.2	< .001	< .001	.256
P4	Brightness	Bladder Pain	0.006	-0.003	0.015	0.005	1.24	0.69	1.8	.182	.985	.012
P4	Brightness	Menstrual Pain	0.006	0.001	0.012	0.003	3.71	0.69	5.4	.022	.117	.036
P4	Brightness	Somatic Symptoms	-0.044	-0.103	0.015	0.030	1.48	0.69	2.1	.145	.58	.015
P7	Brightness	Intercept	0.425	0.279	0.571	0.074	26.51	0.80	33.0	< .001	< .001	.188
P7	Brightness	Bladder Pain	-0.003	-0.013	0.007	0.005	0.28	0.80	0.3	.559	.985	.002
P7	Brightness	Menstrual Pain	0.008	0.002	0.014	0.003	6.34	0.80	7.9	.006	.09	.052
P7	Brightness	Somatic Symptoms	-0.027	-0.091	0.037	0.032	0.55	0.80	0.7	.408	.817	.005
P8	Brightness	Intercept	0.437	0.298	0.576	0.070	28.11	0.73	38.6	< .001	< .001	.213
P8	Brightness	Bladder Pain	0.003	-0.006	0.012	0.005	0.29	0.73	0.4	.525	.985	.003
P8	Brightness	Menstrual Pain	0.007	0.001	0.012	0.003	4.20	0.73	5.8	.018	.113	.039
P8	Brightness	Somatic Symptoms	-0.078	-0.139	-0.017	0.031	4.68	0.73	6.4	.012	.197	.043
Pz	Brightness	Intercept	0.425	0.291	0.560	0.068	26.56	0.68	39.1	< .001	< .001	.215
Pz	Brightness	Bladder Pain	0.000	-0.009	0.009	0.005	0.00	0.68	0.0	.964	.985	< .001
Pz	Brightness	Menstrual Pain	0.005	0.000	0.010	0.003	2.32	0.68	3.4	.067	.134	.023
Pz	Brightness	Somatic Symptoms	-0.017	-0.076	0.042	0.030	0.22	0.68	0.3	.568	.896	.002
T7	Brightness	Intercept	0.341	0.147	0.535	0.098	17.09	1.41	12.1	.001	.001	.078
T7	Brightness	Bladder Pain	0.000	-0.013	0.013	0.007	0.00	1.41	0.0	.979	.985	< .001



T7	Brightness	Menstrual Pain	0.001	-0.007	0.009	0.004	0.12	1.41	0.1	.773	.773	.001
T7	Brightness	Somatic Symptoms	-0.007	-0.091	0.078	0.043	0.03	1.41	0.0	.877	.934	< .001
T8	Brightness	Intercept	0.459	0.312	0.605	0.074	30.94	0.81	38.4	< .001	< .001	.211
T8	Brightness	Bladder Pain	0.004	-0.006	0.013	0.005	0.41	0.81	0.5	.478	.985	.004
T8	Brightness	Menstrual Pain	0.006	0.000	0.011	0.003	2.75	0.81	3.4	.067	.134	.023
T8	Brightness	Somatic Symptoms	0.009	-0.055	0.073	0.032	0.06	0.81	0.1	.779	.934	.001
TP10	Brightness	Intercept	0.410	0.261	0.558	0.075	24.67	0.83	29.7	< .001	< .001	.172
TP10	Brightness	Bladder Pain	0.004	-0.006	0.014	0.005	0.53	0.83	0.6	.427	.985	.004
TP10	Brightness	Menstrual Pain	0.002	-0.004	0.008	0.003	0.40	0.83	0.5	.49	.523	.003
TP10	Brightness	Somatic Symptoms	0.004	-0.061	0.069	0.033	0.01	0.83	0.0	.905	.934	< .001
TP9	Brightness	Intercept	0.617	0.375	0.860	0.123	56.05	2.22	25.3	< .001	< .001	.15
TP9	Brightness	Bladder Pain	0.007	-0.009	0.023	0.008	1.59	2.22	0.7	.398	.985	.005
TP9	Brightness	Menstrual Pain	0.008	-0.002	0.018	0.005	6.17	2.22	2.8	.097	.153	.019
TP9	Brightness	Somatic Symptoms	-0.061	-0.167	0.045	0.054	2.85	2.22	1.3	.258	.723	.009
C3	PSD	Intercept	0.010	-0.156	0.175	0.084	0.01	1.03	0.0	.91	.945	< .001
C3	PSD	Bladder Pain	0.001	-0.010	0.012	0.006	0.05	1.03	0.1	.819	.974	< .001
C3	PSD	Menstrual Pain	0.000	-0.007	0.006	0.003	0.02	1.03	0.0	.89	.968	< .001
C3	PSD	Somatic Symptoms	-0.023	-0.096	0.049	0.037	0.42	1.03	0.4	.522	.93	.003
C4	PSD	Intercept	0.225	0.079	0.370	0.074	7.42	0.80	9.3	.003	.021	.061
C4	PSD	Bladder Pain	0.009	-0.001	0.019	0.005	2.54	0.80	3.2	.076	.796	.022
C4	PSD	Menstrual Pain	0.002	-0.004	0.008	0.003	0.34	0.80	0.4	.516	.968	.003
C4	PSD	Somatic Symptoms	-0.022	-0.086	0.041	0.032	0.38	0.80	0.5	.491	.93	.003
CP1	PSD	Intercept	0.041	-0.166	0.248	0.105	0.25	1.62	0.2	.697	.779	.001
CP1	PSD	Bladder Pain	-0.011	-0.025	0.003	0.007	3.63	1.62	2.2	.137	.796	.015
CP1	PSD	Menstrual Pain	0.003	-0.005	0.012	0.004	1.09	1.62	0.7	.412	.968	.005
CP1	PSD	Somatic Symptoms	-0.140	-0.231	-0.050	0.046	15.13	1.62	9.4	.003	.043	.061
CP2	PSD	Intercept	0.047	-0.117	0.211	0.083	0.33	1.01	0.3	.569	.701	.002
CP2	PSD	Bladder Pain	0.005	-0.006	0.016	0.006	0.72	1.01	0.7	.4	.916	.005
CP2	PSD	Menstrual Pain	-0.005	-0.012	0.001	0.003	2.73	1.01	2.7	.103	.968	.019
CP2	PSD	Somatic Symptoms	0.051	-0.021	0.122	0.036	1.97	1.01	1.9	.165	.794	.013
CP5	PSD	Intercept	0.125	-0.024	0.274	0.076	2.29	0.84	2.7	.1	.268	.019

CP5	PSD	Bladder Pain	0.001	-0.009	0.011	0.005	0.01	0.84	0.0	.909	.974	< .001
CP5	PSD	Menstrual Pain	0.001	-0.005	0.007	0.003	0.03	0.84	0.0	.858	.968	< .001
CP5	PSD	Somatic Symptoms	-0.035	-0.100	0.031	0.033	0.92	0.84	1.1	.297	.794	.008
CP6	PSD	Intercept	0.202	0.091	0.314	0.056	6.01	0.47	12.9	< .001	.012	.083
CP6	PSD	Bladder Pain	-0.001	-0.009	0.006	0.004	0.05	0.47	0.1	.741	.974	.001
CP6	PSD	Menstrual Pain	0.000	-0.005	0.004	0.002	0.00	0.47	0.0	.968	.968	< .001
CP6	PSD	Somatic Symptoms	0.088	0.040	0.137	0.025	5.99	0.47	12.8	< .001	.015	.082
Cz	PSD	Intercept	0.062	-0.091	0.215	0.077	0.57	0.88	0.6	.423	.618	.005
Cz	PSD	Bladder Pain	0.006	-0.004	0.017	0.005	1.31	0.88	1.5	.225	.796	.01
Cz	PSD	Menstrual Pain	0.000	-0.006	0.006	0.003	0.00	0.88	0.0	.948	.968	< .001
Cz	PSD	Somatic Symptoms	0.009	-0.058	0.076	0.034	0.06	0.88	0.1	.79	.931	< .001
F3	PSD	Intercept	0.039	-0.146	0.224	0.094	0.22	1.29	0.2	.68	.779	.001
F3	PSD	Bladder Pain	0.001	-0.011	0.014	0.006	0.05	1.29	0.0	.849	.974	< .001
F3	PSD	Menstrual Pain	0.001	-0.007	0.008	0.004	0.03	1.29	0.0	.88	.968	< .001
F3	PSD	Somatic Symptoms	-0.053	-0.134	0.028	0.041	2.15	1.29	1.7	.199	.794	.012
F4	PSD	Intercept	0.176	-0.024	0.376	0.101	4.57	1.50	3.0	.083	.242	.021
F4	PSD	Bladder Pain	-0.001	-0.015	0.012	0.007	0.05	1.50	0.0	.856	.974	< .001
F4	PSD	Menstrual Pain	-0.002	-0.010	0.006	0.004	0.43	1.50	0.3	.594	.968	.002
F4	PSD	Somatic Symptoms	-0.017	-0.104	0.070	0.044	0.22	1.50	0.1	.7	.931	.001
F7	PSD	Intercept	0.150	-0.044	0.343	0.098	3.29	1.41	2.3	.129	.283	.016
F7	PSD	Bladder Pain	0.003	-0.010	0.016	0.007	0.22	1.41	0.2	.692	.974	.001
F7	PSD	Menstrual Pain	-0.001	-0.008	0.007	0.004	0.03	1.41	0.0	.893	.968	< .001
F7	PSD	Somatic Symptoms	-0.003	-0.088	0.081	0.043	0.01	1.41	0.0	.941	.941	< .001
F8	PSD	Intercept	0.195	0.019	0.371	0.089	5.61	1.17	4.8	.03	.16	.033
F8	PSD	Bladder Pain	0.002	-0.010	0.014	0.006	0.10	1.17	0.1	.767	.974	.001
F8	PSD	Menstrual Pain	0.002	-0.005	0.009	0.004	0.25	1.17	0.2	.642	.968	.002
F8	PSD	Somatic Symptoms	-0.042	-0.119	0.035	0.039	1.34	1.17	1.2	.285	.794	.008
FC1	PSD	Intercept	-0.210	-0.594	0.173	0.194	6.50	5.54	1.2	.28	.472	.008
FC1	PSD	Bladder Pain	-0.017	-0.043	0.008	0.013	9.89	5.54	1.8	.184	.796	.012
FC1	PSD	Menstrual Pain	-0.007	-0.022	0.009	0.008	4.08	5.54	0.7	.392	.968	.005
FC1	PSD	Somatic Symptoms	0.042	-0.126	0.210	0.085	1.36	5.54	0.2	.62	.931	.002

FC2	PSD	Intercept	0.119	-0.070	0.308	0.096	2.09	1.35	1.6	.215	.404	.011
FC2	PSD	Bladder Pain	-0.007	-0.020	0.005	0.006	1.80	1.35	1.3	.249	.796	.009
FC2	PSD	Menstrual Pain	0.004	-0.003	0.012	0.004	1.66	1.35	1.2	.268	.968	.009
FC2	PSD	Somatic Symptoms	-0.035	-0.117	0.048	0.042	0.93	1.35	0.7	.407	.868	.005
FC5	PSD	Intercept	-0.006	-0.172	0.160	0.084	0.00	1.04	0.0	.945	.945	< .001
FC5	PSD	Bladder Pain	-0.007	-0.018	0.005	0.006	1.44	1.04	1.4	.241	.796	.01
FC5	PSD	Menstrual Pain	0.004	-0.002	0.011	0.003	1.80	1.04	1.7	.189	.968	.012
FC5	PSD	Somatic Symptoms	-0.010	-0.083	0.062	0.037	0.08	1.04	0.1	.782	.931	.001
FC6	PSD	Intercept	0.008	-0.162	0.179	0.086	0.01	1.09	0.0	.924	.945	< .001
FC6	PSD	Bladder Pain	0.010	-0.001	0.022	0.006	3.51	1.09	3.2	.075	.796	.022
FC6	PSD	Menstrual Pain	0.001	-0.006	0.008	0.003	0.15	1.09	0.1	.716	.968	.001
FC6	PSD	Somatic Symptoms	0.007	-0.068	0.082	0.038	0.04	1.09	0.0	.853	.931	< .001
Fp1	PSD	Intercept	0.035	-0.150	0.221	0.094	0.18	1.29	0.1	.706	.779	.001
Fp1	PSD	Bladder Pain	0.006	-0.007	0.018	0.006	1.00	1.29	0.8	.381	.916	.005
Fp1	PSD	Menstrual Pain	-0.001	-0.008	0.007	0.004	0.03	1.29	0.0	.887	.968	< .001
Fp1	PSD	Somatic Symptoms	0.054	-0.027	0.135	0.041	2.26	1.29	1.8	.188	.794	.012
Fp2	PSD	Intercept	0.092	-0.141	0.325	0.118	1.25	2.04	0.6	.435	.618	.004
Fp2	PSD	Bladder Pain	0.004	-0.011	0.020	0.008	0.59	2.04	0.3	.593	.974	.002
Fp2	PSD	Menstrual Pain	0.001	-0.009	0.010	0.005	0.05	2.04	0.0	.874	.968	< .001
Fp2	PSD	Somatic Symptoms	-0.060	-0.161	0.042	0.052	2.74	2.04	1.3	.249	.794	.009
FT10	PSD	Intercept	0.152	-0.010	0.315	0.082	3.42	0.99	3.5	.065	.236	.024
FT10	PSD	Bladder Pain	-0.005	-0.016	0.006	0.006	0.83	0.99	0.8	.361	.916	.006
FT10	PSD	Menstrual Pain	0.001	-0.006	0.007	0.003	0.04	0.99	0.0	.833	.968	< .001
FT10	PSD	Somatic Symptoms	-0.037	-0.108	0.034	0.036	1.07	0.99	1.1	.299	.794	.008
FT9	PSD	Intercept	0.067	-0.146	0.279	0.108	0.65	1.70	0.4	.536	.701	.003
FT9	PSD	Bladder Pain	0.003	-0.012	0.017	0.007	0.24	1.70	0.1	.706	.974	.001
FT9	PSD	Menstrual Pain	-0.002	-0.010	0.007	0.004	0.34	1.70	0.2	.657	.968	.001
FT9	PSD	Somatic Symptoms	0.080	-0.013	0.172	0.047	4.87	1.70	2.9	.093	.794	.02
Fz	PSD	Intercept	0.086	-0.128	0.300	0.108	1.08	1.72	0.6	.428	.618	.004
Fz	PSD	Bladder Pain	-0.005	-0.019	0.009	0.007	0.84	1.72	0.5	.486	.973	.003
Fz	PSD	Menstrual Pain	-0.001	-0.009	0.008	0.004	0.06	1.72	0.0	.852	.968	< .001

Fz	PSD	Somatic Symptoms	-0.006	-0.099	0.088	0.047	0.03	1.72	0.0	.902	.931	< .001
O1	PSD	Intercept	0.089	-0.045	0.222	0.067	1.15	0.67	1.7	.192	.383	.012
O1	PSD	Bladder Pain	0.007	-0.002	0.016	0.005	1.50	0.67	2.2	.137	.796	.015
O1	PSD	Menstrual Pain	-0.005	-0.010	0.001	0.003	2.05	0.67	3.1	.082	.968	.021
O1	PSD	Somatic Symptoms	0.006	-0.052	0.064	0.029	0.03	0.67	0.0	.838	.931	< .001
O2	PSD	Intercept	0.075	-0.057	0.207	0.067	0.83	0.65	1.3	.262	.466	.009
O2	PSD	Bladder Pain	-0.006	-0.014	0.003	0.004	0.99	0.65	1.5	.22	.796	.01
O2	PSD	Menstrual Pain	0.001	-0.004	0.007	0.003	0.14	0.65	0.2	.643	.968	.002
O2	PSD	Somatic Symptoms	-0.006	-0.064	0.051	0.029	0.03	0.65	0.0	.827	.931	< .001
Oz	PSD	Intercept	0.107	0.040	0.174	0.034	1.68	0.17	9.9	.002	.021	.065
Oz	PSD	Bladder Pain	0.005	0.001	0.010	0.002	0.83	0.17	4.9	.029	.796	.033
Oz	PSD	Menstrual Pain	-0.001	-0.004	0.002	0.001	0.12	0.17	0.7	.404	.968	.005
Oz	PSD	Somatic Symptoms	-0.005	-0.034	0.025	0.015	0.02	0.17	0.1	.75	.931	.001
P3	PSD	Intercept	0.100	-0.012	0.212	0.057	1.46	0.47	3.1	.081	.242	.021
P3	PSD	Bladder Pain	0.001	-0.007	0.008	0.004	0.02	0.47	0.1	.821	.974	< .001
P3	PSD	Menstrual Pain	0.003	-0.001	0.008	0.002	0.85	0.47	1.8	.182	.968	.012
P3	PSD	Somatic Symptoms	-0.028	-0.077	0.021	0.025	0.61	0.47	1.3	.26	.794	.009
P4	PSD	Intercept	0.083	-0.025	0.192	0.055	1.01	0.44	2.3	.132	.283	.016
P4	PSD	Bladder Pain	-0.002	-0.009	0.005	0.004	0.11	0.44	0.3	.615	.974	.002
P4	PSD	Menstrual Pain	-0.003	-0.007	0.002	0.002	0.64	0.44	1.4	.231	.968	.01
P4	PSD	Somatic Symptoms	0.007	-0.041	0.054	0.024	0.03	0.44	0.1	.782	.931	.001
P7	PSD	Intercept	0.117	-0.001	0.235	0.060	2.02	0.52	3.9	.051	.235	.026
P7	PSD	Bladder Pain	0.003	-0.005	0.011	0.004	0.37	0.52	0.7	.401	.916	.005
P7	PSD	Menstrual Pain	-0.003	-0.008	0.002	0.002	0.83	0.52	1.6	.208	.968	.011
P7	PSD	Somatic Symptoms	0.026	-0.026	0.077	0.026	0.51	0.52	1.0	.323	.794	.007
P8	PSD	Intercept	0.199	0.085	0.313	0.058	5.84	0.49	11.9	.001	.012	.077
P8	PSD	Bladder Pain	0.000	-0.008	0.008	0.004	0.00	0.49	0.0	.974	.974	< .001
P8	PSD	Menstrual Pain	0.001	-0.004	0.005	0.002	0.03	0.49	0.1	.814	.968	< .001
P8	PSD	Somatic Symptoms	0.021	-0.029	0.071	0.025	0.34	0.49	0.7	.405	.868	.005
Pz	PSD	Intercept	0.156	0.053	0.260	0.052	3.60	0.40	9.0	.003	.021	.059
Pz	PSD	Bladder Pain	0.002	-0.005	0.009	0.004	0.17	0.40	0.4	.518	.974	.003

Pz	PSD	Menstrual Pain	0.003	-0.001	0.007	0.002	0.69	0.40	1.7	.192	.968	.012
Pz	PSD	Somatic Symptoms	-0.015	-0.060	0.030	0.023	0.16	0.40	0.4	.523	.93	.003
T7	PSD	Intercept	0.258	-0.018	0.534	0.140	9.79	2.86	3.4	.066	.236	.023
T7	PSD	Bladder Pain	-0.003	-0.022	0.015	0.009	0.38	2.86	0.1	.718	.974	.001
T7	PSD	Menstrual Pain	0.005	-0.006	0.016	0.006	2.08	2.86	0.7	.395	.968	.005
T7	PSD	Somatic Symptoms	-0.024	-0.145	0.096	0.061	0.45	2.86	0.2	.693	.931	.001
T8	PSD	Intercept	0.050	-0.120	0.220	0.086	0.37	1.08	0.3	.562	.701	.002
T8	PSD	Bladder Pain	-0.004	-0.016	0.007	0.006	0.61	1.08	0.6	.455	.97	.004
T8	PSD	Menstrual Pain	0.000	-0.007	0.007	0.003	0.00	1.08	0.0	.964	.968	< .001
T8	PSD	Somatic Symptoms	-0.052	-0.126	0.022	0.038	2.08	1.08	1.9	.168	.794	.013
TP10	PSD	Intercept	0.098	-0.026	0.222	0.063	1.41	0.58	2.4	.122	.283	.017
TP10	PSD	Bladder Pain	0.000	-0.008	0.009	0.004	0.00	0.58	0.0	.934	.974	< .001
TP10	PSD	Menstrual Pain	0.001	-0.004	0.006	0.003	0.14	0.58	0.2	.625	.968	.002
TP10	PSD	Somatic Symptoms	-0.004	-0.058	0.050	0.027	0.01	0.58	0.0	.881	.931	< .001
TP9	PSD	Intercept	-0.072	-0.257	0.113	0.094	0.76	1.29	0.6	.444	.618	.004
TP9	PSD	Bladder Pain	0.000	-0.012	0.013	0.006	0.00	1.29	0.0	.956	.974	< .001
TP9	PSD	Menstrual Pain	-0.003	-0.010	0.005	0.004	0.76	1.29	0.6	.443	.968	.004
TP9	PSD	Somatic Symptoms	0.007	-0.074	0.087	0.041	0.03	1.29	0.0	.874	.931	< .001

*Note.* Results for the Intercept model are equivalent across all electrodes and are therefore not presented for each individual electrode; *df* for the numerator and denominator were 1 and 143, respectively; LL = lower level; UL = upper level.